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Abstract
A method for determining improved innate immunity, disease resistance or performance in animals is
disclosed. The method involves assays for a genetic differences in the NRAMP1 gene of the animal which is
associated with superior disease resistance. Novel NRAMP1 sequence, assays, and compositions for
identifying the presence of absence of these alleles are provided.
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GENETIC MARKERS FOR SCREENING 
ANIMALS FOR IMPROVED DISEASE 
RESISTANCE (NRAMP) 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application claims bene?t under 35 USC §119(e) 
of provisional application 60/294,757 ?led May 31, 2001. 
GRANT REFERENCE 
Work for this invention Was funded in part by ISU Grant 
No. 400-43-71-21-3337. The Government may have certain 
rights in this invention. 
FIELD OF THE INVENTION 
This invention relates generally to the detection of genetic 
differences among animals. More particularly, the invention 
relates to genetic markers Which have been identi?ed in 
several genes indicative of heritable phenotypes associated 
With improved traits, such as disease resistance and innate 
immunity. Methods and compositions for use of these mark 
ers in genotyping of animals and selection are also disclosed. 
BACKGROUND OF THE INVENTION 
Genetic differences exist among individual animals as 
Well as among breeds Which can be exploited by breeding 
techniques to achieve animals With desirable characteristics. 
For example, Chinese pig breeds are knoWn for reaching 
puberty at an early age and for their large litter siZe, While 
American breeds are knoWn for their greater groWth rates 
and leanness. Often, hoWever, heritability for desired traits 
is loW, and standard breeding methods Which select indi 
viduals based upon phenotypic variations do not take fully 
into account genetic variability or complex gene interactions 
Which exist. 
There is a continuing need for an approach that deals With 
selection for disease resistance at the cellular or DNA level. 
This method Will provide the ability to genetically evaluate 
animals and to enable breeders to more accurately select 
those animals Which not only phenotypically express desir 
able traits but those Which express favorable underlying 
genetic criteria. This has largely been accomplished to date 
by marker-assisted selection. 
RFLP analysis has been used by several groups to study 
pig DNA. Jung et al., Theor. Appl. Genet., 77:271—274 
(1989), incorporated herein by reference, discloses the use 
of RFLP techniques to shoW genetic variability betWeen tWo 
pig breeds. Polymorphism Was demonstrated for sWine 
leukocyte antigen (SLA) Class I genes in these breeds. 
Hoganson et al., Abstract for Annual Meeting of MidWestern 
Section of the American Society of Animal Science, Mar. 
26—28, 1990, incorporated herein by reference, reports on 
the polymorphism of sWine major histocompatibility com 
plex (MHC) genes for Chinese pigs, also demonstrated by 
RFLP analysis. Jung et al. Animal Genetics, 26:79—91 
(1989), incorporated herein by reference, reports on RFLP 
analysis of SLA Class I genes in certain boars. The authors 
state that the results suggest that there may be an association 
betWeen sWine SLA/MHC Class I genes and production and 
performance traits. They further state that the use of SLA 
Class I restriction fragments, as genetic markers, may have 
potential in the future for improving pig groWth perfor 
mance. 
The ability to folloW a speci?c favorable genetic allele 
involves a novel and lengthy process of the identi?cation of 
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a DNA molecular marker for a major effect gene. The 
marker may be linked to a single gene With a major effect or 
linked to a number of genes With additive effects. DNA 
markers have several advantages; segregation is easy to 
measure and is unambiguous, and DNA markers are 
co-dominant, i.e., heteroZygous and homoZygous animals 
can be distinctively identi?ed. Once a marker system is 
established, selection decisions could be made very easily, 
since DNA markers can be assayed any time after a tissue or 
blood sample can be collected from the individual infant 
animal, or even an embryo. 
The use of genetic differences in receptor genes has 
become a valuable marker system for selection. For 
example, US. Pat. Nos. 5,550,024 and 5,374,526, issued to 
Rothschild et al., disclose a polymorphism in the pig estro 
gen receptor gene Which is associated With larger litter siZe, 
the disclosure of Which is incorporated herein by reference. 
US. Pat. No. 5,935,784 discloses polymorphic markers in 
the pig prolactin receptor gene Which are associated With 
larger litter siZe and overall reproductive ef?ciency, the 
disclosure of Which is incorporated herein by reference. 
NRAMP1 Gene 
The NRAMP1 gene Was isolated from a murine Bcg 
candidate gene and designated “natural resistance 
associated macrophage protein” gene by Vidal and coWork 
ers (Vidal, et al., Natural resistance to infection With intra 
cellular parasites: isolation of a candidate for Bcg. Cell 73, 
469—485 (1993)). Bcg Was found during genetic studies of 
mice to mediate antimicrobial activity of macrophages 
against intracellular parasites early during infection. The 
isolated NRAMP1 gene apparently encodes an integral 
membrane protein that has structural features similar to 
prokaryotic and eukaryotic ion transporters. More recent 
studies using knockout mice (Vidal, et al., J. Exp. Med. 
182:655—666 (1995)) indicated the NRAMP1 is the Bcg/ 
Lsh/Ity gene (3 genes capable of controlling resistance and 
susceptibility to Mycobacterium bovis (BCG), Leishmania 
donovani and Salmonella typhimurium, respectively, knoWn 
genetically to be a single gene expressed at the macrophage 
level, BlackWell, J. M. The macrophage resistance gene 
Lsh/Ity/Bcg. Res. Immunol. 140: 767 (1989)). It has been 
suggested that the murine NRAMP1 protein might function 
in phagolysosomal membranes as a concentrator of nitric 
oxide, mediating cytocidal activity against the ingested 
parasites of infected macrophage (Vidal, et al. 1993; Malo, 
et al. Genetic control of host resistance to infection. TIG 10, 
365—371 (1994); Cellier, et al. Human natural resistance 
associated macrophage protein: cDNA cloning, chromo 
somal mapping, genomic organiZation, and tissue-speci?c 
expression. J. Exp. Med. 180, 1741—1752 (1994); Malo, et 
al Haplotype mapping and sequence analysis of the mouse 
NRAMP1 gene predicts susceptibility to infection With 
intracellular parasites. Genomics 23, 51—61 (1994)). It has 
recently been indicated that the mammalian NRAMP protein 
family (at least NRAMP 2) functions as broad speci?city 
divalent cation transporters (Gunshin, et al. Nature 388: 482, 
1997; Fleming, et al. Nature Genet. 16: 383, 1997). AcDNA 
for NRAMP1 Was isolated from a pre B-cell cDNA library 
and sequenced. The amino acid sequence for the protein 
product Was deduced from the nucleotide sequence and 
predicts a 53 kDa protein. On the basis of the deduced amino 
acid sequence, Vidal et al. (1993) proposed as a function of 
the NRAMP1 protein the transport of nitrate across the 
membrane of the intracellular vacuole of the macrophage 
containing the microorganisms. In the acid environment of 
this vacuole, the nitrate could be converted via nitrite to 
toxic nitric oxide thereby enhancing killing of the microor 
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ganisms. The NRAMP1 protein has been localized to the 
phagolysosomal membrane, and With the data on NRAMP2 
function, an alternative function has recently been proposed. 
It is knoWn that bacteria use superoxide dismutase (SOD) to 
detoxify the phagolysosome. SOD requires divalent cations, 
notably Mn++. It is proposed that NRAMP1 may pump 
metal ions (such as Fe++ or Mn++) out of the phagolysosome 
compartment, thus depriving bacteria of this defense mecha 
nism (G. Govoni and P. Gros (1998) In?amm. Res. 
47:277—284). 
Nucleotide sequence analyses of murine NRAMP1 cDNA 
shoWed that the susceptible phenotype Was associated With 
a nonconservative glycine-to-aspartic acid amino acid sub 
stitution Within the second trans membrane domain of the 
protein (Vidal, et al. 1993). 
Whatever the mechanism of NRAMP1, it has been rec 
ogniZed as important for its role in infection resistance in 
several other species, in addition to mice. Its homologues, 
variants and polymorphisms have been investigated in 
humans and agriculturally important animals, With unpre 
dictable results for use of these variants as markers of any 
phenotype. For example, see, international application WO 
95/13371 to Gros et al. 
Gros et al. discloses mouse and human cDNAs from 
NRAMP1 genes. The nucleotide sequences of mouse and 
human cDNAs are disclosed, as are the amino acid 
sequences. Throughout the document a potential use for the 
nucleotide sequences is disclosed as assaying for different 
mutations or variability Which is associated With suscepti 
bility or resistance to infectious diseases including 
tuberculosis, leprosy, salmonellosis, and leshmaniasis. 
The application discloses isolation of the mouse gene 
from a library and the identi?cation of tWo alternate forms 
Bcg’ and Bcgs, Which had a single nucleotide difference, 
namely, a guanine at nucleotide 783, Which Was present in 
resistant strains. Importantly, hoWever, there Were tWo addi 
tional silent mutations detected in the 5‘ portion of the 
transcript from a resistant mice strain, one at nucleotide 
position 563 and another at nucleotide position 1169 Which 
did not have any different phenotypic effect. Out of all 
polymorphisms detected in the tested strains, four out of ?ve 
polymorphisms identi?ed Were silent mutations and Were 
not shoWn to be associated With any difference in suscepti 
bility to infection. 
Application number WO 98/12353 to Templeton et al. 
discloses identi?cation and sequencing of homologues of 
murine NRAMP1 from bovine, bison and other artiodactyla. 
The invention discloses particular sequences of NRAMP1 
Which correlate With resistance or susceptibility to 
brucellosis, tuberculosis, paratuberculosis and salmonellosis 
in cattle. The sequence associated With resistance/ 
susceptibility is a transversion at position 1782 of the 
NRAMP1 cDNA and a polymorphic DNA microsatellite 
sequence difference. 
The examples section discloses cloning of bovine 
NRAMP1 and isolation of bovine NRAMP1 cDNA, analy 
sis of predicted bovine NRAMP1 structure, genetic mapping 
of bovine NRAMP1, single-stranded conformational analy 
sis disclosing the microsatellite length polymorphism, cell 
speci?c expression of bovine NRAMP1 mRNA, SSCA 
disclosing a 3‘ untranslated region polymorphism, and asso 
ciation of resistances or susceptibility to ruminant 
brucellosis, tuberculosis, paratuberculosis and 
salmonellosis, With the alternative gene forms. 
The Barton et al. application, WO 95/20044, discloses the 
sequence of NRAMP1 gene isolated from mice. Function 
and uses of the gene include diagnosing the susceptibility or 
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resistance to microorganisms including Salmonella 
zfyphimurium, Leishmania donovani and Mycobacterium 
bovis. A resistant allele of murine NRAMP1 Was found With 
tWo silent mutations, one at 359 base pairs and one at 965 
base pairs. In humans a polymorphic repeat in the 5‘ pro 
moter region Was identi?ed, With no association With a 
useful trait disclosed. 
The Rotter et al. reference (WO 99/23255) relates to a 
method of identifying novel alleles or allelic combinations 
in the human NRAMP1 locus Which evidence statistically 
signi?cant correlation With one or more biological responses 
(humans With diseases), such as Crohn’s Disease, Ulcerative 
Colitis or their subtypes. Seven alleles of the NRAMP1 
satellite marker Were studied. The D2S434 allele is charac 
teriZed by seven different fragment siZes from 262 base pairs 
to 286 base pairs characteriZed by repeats of GATA(N). The 
2DS1323 NRAMP1 allele Was identi?ed in tWo forms of 
GATA(N) repeats, one of 324 base pairs and one of 328 base 
pairs. The D2S1323 polymorphism and D2S434 polymor 
phism Were analyZed for linkage to various diseases. Three 
mutated and Wild type NRAMP1 DNA sequences Were also 
obtained from patients, and associations for some of the 
alleles Were found With in?ammatory boWel disease and 
ulcerative colitis. 
As can be seen, the NRAMP1 gene is knoWn to be 
variable and it is highly unpredictable as to Which if any 
variations are associated With useful traits to be of value as 
a genetic marker. 
The present invention provides a genetic markers, based 
upon the discovery of a polymorphisms in the porcine 
NRAMP1 gene, Which correlate With resistance or suscep 
tibility to pathogenic infection in pigs. This Will permit 
genetic typing of pigs for their NRAMP1 allele and for 
determination of the relationship of speci?c RFLPs to resis 
tance to infection. It Will also permit the identi?cation of 
individual males and females that carry the gene for 
improved resistance. Thus, the markers may be selection 
tools in breeding programs to develop lines and breeds that 
produce litters containing more resistant offspring. Also 
disclosed are novel porcine NRAMP1 genomic sequences, 
as Well as primers for assays to identify the presence or 
absence of marker alleles. 
According to the invention a polymorphism Was identi 
?ed in the NRAMP1 gene Which is associated With the 
improved resistance to pathogenic infection. 
It is an object of the invention to provide a method of 
screening pigs to determine those more likely to produce 
offspring With improved pathogenic resistance, in the 
NRAMP1 gene. 
Another object of the invention is to provide a method for 
identifying genetic markers for improved disease resistance. 
A further object of the invention is to provide genetic 
markers for selection and breeding to obtain pigs that Will be 
expected to have a loWer susceptibility to infection than 
those Without the favorable allele. 
Yet another object of the invention is to provide a kit for 
evaluating a sample of pig DNA for speci?c genetic markers 
of disease resistance. 
Additional objects and advantages of the invention Will be 
set forth in part in the description that folloWs, and in part 
Will be obvious from the description, or may be learned by 
the practice of the invention. The objects and advantages of 
the invention Will be attained by means of the instrumen 
tality’s and combinations particularly pointed out in the 
appended claims. 
SUMMARY OF THE INVENTION 
To achieve the objects and in accordance With the purpose 
of the invention, as embodied and broadly described herein, 
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the present invention provides a method for screening ani 
mals to determine those more likely to have biologically 
different phenotypes such as, or associated With, improved 
innate immunity, disease resistance or resistance to bacterial 
infection, as evidenced by factors including but not limited 
to bacterial count, lymphocyte count, neutrophil count, or 
monocyte count after challenge to identify animals Which 
have superior bacterial killing, or ability to stave off infec 
tion in a particular population, When bred, or raised or to 
select against pigs Which have alleles indicating unfavorable 
phenotypes. These traits also may be observed by assaying 
for traits associated With overall improved health. As used 
herein the term “disease resistance” or “innate immunity” 
shall mean an ability to stave off infection that is biologically 
different to that Which is observed When the favorable allele 
is not present as evidenced by measurements included but 
not limited to average lymphocyte count and percentage, 
monocyte count, neutrophil count and percentage and bac 
terial count after challenge or other measurements of innate 
immunity. This can include other indicia of animals associ 
ated With a good immune system and overall health such as 
Weight gain, feed ef?ciency, or other indicia of overall health 
of animals. 
Thus, the present invention provides a method for screen 
ing pigs to determine those more likely to have the improved 
trait of superior disease resistance and/or those less likely to 
demonstrate those traits Which method comprises the steps: 
1) obtaining a sample of tissue or genomic DNA from an 
animal; and 2) analyZing the mRNA or genomic DNA 
obtained in 1) to determine Which allele(s) is/are present. 
Brie?y, the sample of genetic material analyZed to determine 
the presence or absence of a particular allele that is corre 
lated With a desirable trait, or one Which is linked thereto. 
As is Well knoWn to those of skill in the art, a variety of 
techniques may be utiliZed When comparing nucleic acid 
molecules for sequence differences. These include by Way of 
example, restriction fragment length polymorphism 
analysis, heteroduplex analysis, single strand conformation 
polymorphism analysis, denaturing gradient electrophoresis 
and temperature gradient electrophoresis. 
In one embodiment, the polymorphism is a restriction 
fragment length polymorphism (RFLP) and the assay com 
prises identifying the gene from isolated genetic material; 
exposing the gene to a restriction enZyme that yields restric 
tion fragments of the gene of varying length; separating the 
restriction fragments to form a restriction pattern, such as by 
electrophoresis or HPLC separation; and comparing the 
resulting restriction fragment pattern from an animal gene 
that is either knoWn to have or not to have the desired 
marker. If an animal tests positive for the marker (or allele), 
such animal can be considered for inclusion in the breeding 
program. If the animal does not test positive for the marker 
genotype, the animal can be culled from the group and 
otherWise used. 
In a most preferred embodiment, the gene, or a fragment 
thereof, is isolated by the use of primers and DNA poly 
merase to amplify a speci?c region of the gene Which 
contains the polymorphism or a polymorphism linked 
thereto. Next, the ampli?ed region is either directly sepa 
rated or sequenced or is digested With a restriction enZyme 
and fragments are again separated. Visualization of the 
separated fragments, or RFLP pattern, is by simple staining 
of the fragments, or by labeling the primers or the nucleoside 
triphosphates used in ampli?cation. 
In another embodiment, the invention comprises a method 
for identifying a genetic marker for disease resistance traits, 
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such as bacterial counts, lymphocyte count, neutrophil 
count, or monocyte count after challenge. Male and female 
animals of the same breed, breed cross, or similar genetic 
lineage are bred, and the disease resistance traits are deter 
mined. A polymorphism in the gene of each animal is 
identi?ed and associated With the desired trait(s). Preferably, 
PCR-RFLP analysis is used to determine the polymorphism. 
It is also possible to establish linkage betWeen speci?c 
alleles of alternative DNA markers and alleles of DNA 
markers knoWn to be associated With a particular gene (e.g., 
the NRAMP1 gene discussed herein) Which have previously 
been shoWn to be associated With a particular trait. Thus, in 
the present situation, taking a particular gene, it Would be 
possible, at least in the short term, to select for pigs, or other 
animals, likely to have superior disease resistance or ability 
to stave off infection, or alternatively, against pigs likely to 
have inferior traits, indirectly, by selecting for certain alleles 
of a particular gene associated With the marker alleles 
through the selection of speci?c linked alleles of alternative 
chromosome markers. Thus, in the present situation, taking 
the NRAMP1 gene, it Would be possible, at least in the short 
term, to select for pigs likely to produce disease resistance, 
or alternatively, against pigs likely to produce susceptible 
litters indirectly, by selecting for certain alleles of the 
NRAMP1 associated marker through the selection of spe 
ci?c alleles of alternative markers located on chromosome 
15 as NRAMP1 is. See Sun et al., Animal Genetics, 1998, 
29:138—140 for mapping of NRAMP1 and linkage. Accord 
ing to the invention, examples of markers on the published 
PiGMaP chromosome 15 map Which are linked to the 
NRAMP1 gene are S0149, S0784, S0088, and DPP4. 
The invention further comprises a kit for evaluating a 
sample of DNA for the presence in genetic material of a 
desired genetic marker located in the gene indicative of a 
inheritable trait of disease resistance or ability to stave off 
infection. At a minimum, the kit is a container With one or 
more reagents that identify a polymorphism in the porcine 
NRAMP1 gene. Preferably, the reagent is a set of oligo 
nucleotide primers capable of amplifying a fragment of the 
selected gene that contains a polymorphism. Preferably, the 
kit further contains a restriction enZyme that cleaves the 
gene in at least one place, alloWing for separation of 
fragments and detection of polymorphic loci. 
DETAILED DESCRIPTION OF THE FIGURES 
FIG. 1 is the 536 bp PCR product (SEQ ID NO: 3) 
ampli?ed With SEQ ID NOS: 1 and 2 primers. Exon 2 
sequence is in italic text. Primers are shoWn in bold (forWard 
sequence of the 5‘ primer and reverse complement of the 3‘ 
primer sequence is shoWn). 
FIG. 2 is the 615 bp PCR product (SEQ ID NO: 4) 
ampli?ed With SEQ ID NOS: 5 and 6 primers. The primers 
again are in bold spanning exon 14—15 (forWard sequence of 
the 5‘ primer and reverse complement of the 3‘ primer 
sequence is shoWn). Intron 14 is in italics. 
FIG. 3 is the 934 bp PCR product (SEQ ID NO: 7) 
ampli?ed With SEQ ID NOS: 8 and 9 primers. The primers 
again are in bold (forWard sequence of the 5‘ primer and 
reverse complement of the 3‘ primer sequence is shoWn). 
DETAILED DESCRIPTION OF THE 
INVENTION 
Reference Will noW be made in detail to the presently 
preferred embodiments of the invention, Which together 
With the folloWing examples, serve to explain the principles 
of the invention. All references cited herein are hereby 
expressly incorporated by reference. 
US 6,844,159 B2 
7 
The invention relates to the identi?cation of quantitative 
trait loci (QTL) for improved disease resistance or resistance 
to pathogen infection, including, but not limited to, 
Salmonellosis, identi?able by traits such as bacterial count, 
total or speci?c leukocyte counts (including white blood 
cells, lymphocytes, monocytes, neutrophils) before and/or 
after infection, or leukocyte function to identify pigs and 
other animals which have superior pathogen killing or 
ability to stave off infection. It provides a method of 
screening animals to determine those more likely to have 
improved resistance and/or good immune system and overall 
health traits (as shown by measures such as weight gain or 
feed efficiency) when bred by identifying the presence or an 
absence of a polymorphism in certain genes (NRAMP1) that 
are correlated with these traits. 
Thus, the invention relates to genetic markers and meth 
ods of identifying those markers in a pig or other animal of 
a particular breed, strain, population, or group, whereby an 
animal has disease resistance above the mean for that 
particular breed, strain, population, or group. 
The marker may be identi?ed by any method known to 
one of ordinary skill in the art which identi?es the presence 
or absence of the particular allele or marker, including, for 
example, direct sequencing single-strand conformation 
polymorphism analysis (SSCP), base excision sequence 
scanning (BESS), RFLP analysis, heteroduplex analysis, 
denaturing gradient gel electrophoresis, allelic PCR, tem 
perature gradient electrophoresis, ligase chain reaction, 
direct sequencing, minisequencing, nucleic acid 
hybridization, and micro-array-type detection of the 
NRAMP1 gene, or other linked sequences, and examination 
for a polymorphic site. Yet another technique includes an 
Invader Assay which includes isothermic ampli?cation that 
relies on a catalytic release of ?uorescence. See Third Wave 
Technology at www.twt.com. All of these techniques are 
intended to be within the scope of the invention. A brief 
description of these techniques follows. 
Isolation and Ampli?cation of Nucleic Acid 
Samples of patient, proband, test subject, or family mem 
ber genomic DNA are isolated from any convenient source 
including saliva, buccal cells, hair roots, blood, cord blood, 
amniotic ?uid, interstitial ?uid, peritoneal ?uid, chorionic 
villus, and any other suitable cell or tissue sample with intact 
interphase nuclei or metaphase cells. The cells can be 
obtained from solid tissue as from a fresh or preserved organ 
or from a tissue sample or biopsy. The sample can contain 
compounds which are not naturally intermixed with the 
biological material such as preservatives, anticoagulants, 
buffers, ?xatives, nutrients, antibiotics, or the like. 
Methods for isolation of genomic DNA from these vari 
ous sources are described in, for example, Kirby, DNA 
Fingerprinting, An Introduction, W. H. Freeman & Co. New 
York (1992). Genomic DNA can also be isolated from 
cultured primary or secondary cell cultures or from trans 
formed cell lines derived from any of the aforementioned 
tissue samples. 
Samples of patient, proband, test subject or family mem 
ber RNA can also be used. RNA can be isolated from tissues 
expressing the NRAMP1 gene as described in Sambrook et 
al., supra. RNA can be total cellular RNA, mRNA, poly A+ 
RNA, or any combination thereof. For best results, the RNA 
is puri?ed, but can also be unpuri?ed cytoplasmic RNA. 
RNA can be reverse transcribed to form DNA which is then 
used as the ampli?cation template, such that the PCR 
indirectly ampli?es a speci?c population of RNA transcripts. 
See, e.g., Sambrook, supra, Kawasaki et al., Chapter 8 in 
PCR Technology, (1992) supra, and Berg et al., Hum. Genet. 
85:655—658 (1990). 
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PCR Ampli?cation 
The most common means for ampli?cation is polymerase 
chain reaction (PCR), as described in US. Pat. Nos. 4,683, 
195, 4,683,202, 4,965,188 each of which is hereby incor 
porated by reference. If PCR is used to amplify the target 
regions in blood cells, hepariniZed whole blood should be 
drawn in a sealed vacuum tube kept separated from other 
samples and handled with clean gloves. For best results, 
blood should be processed immediately after collection; if 
this is impossible, it should be kept in a sealed container at 
4° C. until use. Cells in other physiological ?uids may also 
be assayed. When using any of these ?uids, the cells in the 
?uid should be separated from the ?uid component by 
centrifugation. 
Tissues should be roughly minced using a sterile, dispos 
able scalpel and a sterile needle (or two scalpels) in a 5 mm 
Petri dish. Procedures for removing paraf?n from tissue 
sections are described in a variety of specialiZed handbooks 
well known to those skilled in the art. 
To amplify a target nucleic acid sequence in a sample by 
PCR, the sequence must be accessible to the components of 
the ampli?cation system. One method of isolating target 
DNA is crude extraction which is useful for relatively large 
samples. Brie?y, mononuclear cells from samples of blood, 
amniocytes from amniotic ?uid, cultured chorionic villus 
cells, or the like are isolated by layering on sterile Ficoll 
Hypaque gradient by standard procedures. Interphase cells 
are collected and washed three times in sterile phosphate 
buffered saline before DNA extraction. If testing DNA from 
peripheral blood lymphocytes, an osmotic shock (treatment 
of the pellet for 10 sec with distilled water) is suggested, 
followed by two additional washings if residual red blood 
cells are visible following the initial washes. This will 
prevent the inhibitory effect of the heme group carried by 
hemoglobin on the PCR reaction. If PCR testing is not 
performed immediately after sample collection, aliquots of 
10° cells can be pelleted in sterile Eppendorf tubes and the 
dry pellet froZen at —20° C. until use. 
The cells are resuspended (106 nucleated cells per 100 pl) 
in a buffer of 50 mM Tris-HCl (pH 8.3), 50 mM KCl 1.5 mM 
MgCl2, 0.5% TWEEN 20 (also known generically as 
Polysorbrate 20), 0.5% NP40 (NONIDET P40) supple 
mented with 100 pig/ml of proteinase K. After incubating at 
56° C. for 2 hr. the cells are heated to 95° C. for 10 min to 
inactivate the proteinase K and immediately moved to wet 
ice (snap-cool). If gross aggregates are present, another 
cycle of digestion in the same buffer should be undertaken. 
Ten pl of this extract is used for ampli?cation. 
When extracting DNA from tissues, e.g., chorionic villus 
cells or con?uent cultured cells, the amount of the above 
mentioned buffer with proteinase K may vary according to 
the siZe of the tissue sample. The extract is incubated for 
4—10 hrs at 50°—60° C. and then at 95° C. for 10 minutes to 
inactivate the proteinase. During longer incubations, fresh 
proteinase K should be added after about 4 hr at the original 
concentration. 
When the sample contains a small number of cells, 
extraction may be accomplished by methods as described in 
Higuchi, “Simple and Rapid Preparation of Samples for 
PCR”, in PCR Technology, Ehrlich, H. A. (ed.), Stockton 
Press, New York, which is incorporated herein by reference. 
PCR can be employed to amplify target regions in very small 
numbers of cells (1000—5000) derived from individual colo 
nies from bone marrow and peripheral blood cultures. The 
cells in the sample are suspended in 20 pl of PCR lysis buffer 
(10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl2, 0.1 
mg/ml gelatin, 0.45% NP40, 0.45% TWEEN 20) and froZen 
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until use. When PCR is to be performed, 0.6 pl of proteinase 
K (2 mg/ml) is added to the cells in the PCR lysis buffer. The 
sample is then heated to about 60° C. and incubated for 1 hr. 
Digestion is stopped through inactivation of the proteinase K 
by heating the samples to 95° C. for 10 min and then cooling 
on ice. 
A relatively easy procedure for extracting DNA for PCR 
is a salting out procedure adapted from the method described 
by Miller et al., Nucleic Acids Res. 16:1215 (1988), Which 
is incorporated herein by reference. Mononuclear cells are 
separated on a Ficoll-Hypaque gradient. The cells are resus 
pended in 3 ml of lysis buffer (10 mM Tris-HCl, 400 mM 
NaCl, 2 mM Na2 EDTA, pH 8.2). Fifty pl of a 20 mg/ml 
solution of proteinase K and 150 pl of a 20% SDS solution 
are added to the cells and then incubated at 37° C. overnight. 
Rocking the tubes during incubation Will improve the diges 
tion of the sample. If the proteinase K digestion is incom 
plete after overnight incubation (fragments are still visible), 
an additional 50 pl of the 20 mg/ml proteinase K solution is 
mixed in the solution and incubated for another night at 37° 
C. on a gently rocking or rotating platform. FolloWing 
adequate digestion, one ml of a 6M NaCl solution is added 
to the sample and vigorously mixed. The resulting solution 
is centrifuged for 15 minutes at 3000 rpm. The pellet 
contains the precipitated cellular proteins, While the super 
natant contains the DNA. The supernatant is removed to a 15 
ml tube that contains 4 ml of isopropanol. The contents of 
the tube are mixed gently until the Water and the alcohol 
phases have mixed and a White DNAprecipitate has formed. 
The DNA precipitate is removed and dipped in a solution of 
70% ethanol and gently mixed. The DNA precipitate is 
removed from the ethanol and air-dried. The precipitate is 
placed in distilled Water and dissolved. 
Kits for the extraction of high-molecular Weight DNA for 
PCR include a Genomic Isolation Kit A.S.A.P. (Boehringer 
Mannheim, Indianapolis, Ind.), Genomic DNA Isolation 
System (GIBCO BRL, Gaithersburg, Md.), Elu-Quik DNA 
Puri?cation Kit (Schleicher & Schuell, Keene, NH), DNA 
Extraction Kit (Stratagene, LaJolla, Calif.), TurboGen Iso 
lation Kit (Invitrogen, San Diego, Calif.), and the like. Use 
of these kits according to the manufacturer’s instructions is 
generally acceptable for puri?cation of DNA prior to prac 
ticing the methods of the present invention. 
The concentration and purity of the extracted DNA can be 
determined by spectrophotometric analysis of the absor 
bance of a diluted aliquot at 260 nm and 280 nm. After 
extraction of the DNA, PCR ampli?cation may proceed. The 
?rst step of each cycle of the PCR involves the separation of 
the nucleic acid duplex formed by the primer extension. 
Once the strands are separated, the next step in PCR 
involves hybridiZing the separated strands With primers that 
?ank the target sequence. The primers are then extended to 
form complementary copies of the target strands. For suc 
cessful PCR ampli?cation, the primers are designed so that 
the position at Which each primer hybridiZes along a duplex 
sequence is such that an extension product synthesiZed from 
one primer, When separated from the template 
(complement), serves as a template for the extension of the 
other primer. The cycle of denaturation, hybridiZation, and 
extension is repeated as many times as necessary to obtain 
the desired amount of ampli?ed nucleic acid. 
In a particularly useful embodiment of PCR ampli?cation, 
strand separation is achieved by heating the reaction to a 
sufficiently high temperature for a sufficient time to cause 
the denaturation of the duplex but not to cause an irrevers 
ible denaturation of the polymerase (see US. Pat. No. 
4,965,188, incorporated herein by reference). Typical heat 
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denaturation involves temperatures ranging from about 80° 
C. to 105° C. for times ranging from seconds to minutes. 
Strand separation, hoWever, can be accomplished by any 
suitable denaturing method including physical, chemical, or 
enZymatic means. Strand separation may be induced by a 
helicase, for example, or an enZyme capable of exhibiting 
helicase activity. For example, the enZyme RecA has heli 
case activity in the presence of ATP. The reaction conditions 
suitable for strand separation by helicases are knoWn in the 
art (see Kuhn Hoffman-Berling, 1978, CSH-Quantitative 
Biology, 43:63—67; and Radding, 1982, Ann. Rev. Genetics 
16:405—436, each of Which is incorporated herein by refer 
ence. 
Template-dependent extension of primers in PCR is cata 
lyZed by a polymeriZing agent in the presence of adequate 
amounts of four deoxyribonucleotide triphosphates 
(typically dATP, dGTP, dCTP, and dTTP) in a reaction 
medium comprised of the appropriate salts, metal cations, 
and pH buffering systems. Suitable polymeriZing agents are 
enZymes knoWn to catalyZe template-dependent DNA syn 
thesis. In some cases, the target regions may encode at least 
a portion of a protein expressed by the cell. In this instance, 
mRNA may be used for ampli?cation of the target region. 
Alternatively, PCR can be used to generate a cDNA library 
from RNA for further ampli?cation, the initial template for 
primer extension is RNA. PolymeriZing agents suitable for 
synthesiZing a complementary, copy-DNA (cDNA) 
sequence from the RNA template are reverse transcriptase 
(RT), such as avian myeloblastosis virus RT, Moloney 
murine leukemia virus RT, or Thermus thermophilus (Tth) 
DNA polymerase, a thermostable DNA polymerase With 
reverse transcriptase activity marketed by Perkin Elmer 
Cetus, Inc. Typically, the genomic RNA template is heat 
degraded during the ?rst denaturation step after the initial 
reverse transcription step leaving only DNA template. Suit 
able polymerases for use With a DNA template include, for 
example, E. coli DNA polymerase I or its KlenoW fragment, 
T4 DNA polymerase, Tth polymerase, and Taq polymerase, 
a heat-stable DNA polymerase isolated from Thermus 
aquaticus and commercially available from Perkin Elmer 
Cetus, Inc. The latter enZyme is Widely used in the ampli 
?cation and sequencing of nucleic acids. The reaction con 
ditions for using Taq polymerase are knoWn in the art and are 
described in Gelfand, 1989, PCR Technology, supra. 
Allele Speci?c PCR 
Allele-speci?c PCR differentiates betWeen target regions 
differing in the presence of absence of a variation or poly 
morphism. PCR ampli?cation primers are chosen Which 
bind only to certain alleles of the target sequence. This 
method is described by Gibbs, Nucleic Acid Res. 
17:12427—2448 (1989). 
Allele Speci?c Oligonucleotide Screening Methods 
Further diagnostic screening methods employ the allele 
speci?c oligonucleotide (ASO) screening methods, as 
described by Saiki et al., Nature 324:163—166 (1986). Oli 
gonucleotides With one or more base pair mismatches are 
generated for any particular allele. ASO screening methods 
detect mismatches betWeen variant target genomic or PCR 
ampli?ed DNA and non-mutant oligonucleotides, shoWing 
decreased binding of the oligonucleotide relative to a mutant 
oligonucleotide. Oligonucleotide probes can be designed 
that under loW stringency Will bind to both polymorphic 
forms of the allele, but Which at high stringency, bind to the 
allele to Which they correspond. Alternatively, stringency 
conditions can be devised in Which an essentially binary 
response is obtained, i.e., an ASO corresponding to a variant 
form of the target gene Will hybridiZe to that allele, and not 
to the Wildtype allele. 
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Ligase Mediated Allele Detection Method 
Target regions of a test subject’s DNA can be compared 
With target regions in unaffected and affected family mem 
bers by ligase-mediated allele detection. See Landegren et 
al., Science 241:107—1080 (1988). Ligase may also be used 
to detect point mutations in the ligation ampli?cation reac 
tion described in Wu et al., Genomics 4:560—569 (1989). 
The ligation ampli?cation reaction (LAR) utiliZes ampli? 
cation of speci?c DNA sequence using sequential rounds of 
template dependent ligation as described in Wu, supra, and 
Barany, Proc. Nat. Acad. Sci. 88:189—193 (1990). 
Denaturing Gradient Gel Electrophoresis 
Ampli?cation products generated using the polymerase 
chain reaction can be analyZed by the use of denaturing 
gradient gel electrophoresis. Different alleles can be identi 
?ed based on the different sequence-dependent melting 
properties and electrophoretic migration of DNA in solution. 
DNA molecules melt in segments, termed melting domains, 
under conditions of increased temperature or denaturation. 
Each melting domain melts cooperatively at a distinct, 
base-speci?c melting temperature Melting domains 
are at least 20 base pairs in length, and may be up to several 
hundred base pairs in length. 
Differentiation betWeen alleles based on sequence speci?c 
melting domain differences can be assessed using polyacry 
lamide gel electrophoresis, as described in Chapter 7 of 
Erlich, ed., PCR Technology, Principles and Applications for 
DNA Ampli?cation, W. H. Freeman and Co., NeW York 
(1992), the contents of Which are hereby incorporated by 
reference. 
Generally, a target region to be analyZed by denaturing 
gradient gel electrophoresis is ampli?ed using PCR primers 
?anking the target region. The ampli?ed PCR product is 
applied to a polyacrylamide gel With a linear denaturing 
gradient as described in Myers et al., Meth. EnZymol. 
155:501—527 (1986), and Myers et al., in Genomic Analysis, 
A Practical Approach, K. Davies Ed. IRL Press Limited, 
Oxford, pp. 95—139 (1988), the contents of Which are hereby 
incorporated by reference. The electrophoresis system is 
maintained at a temperature slightly beloW the Tm of the 
melting domains of the target sequences. 
In an alternative method of denaturing gradient gel 
electrophoresis, the target sequences may be initially 
attached to a stretch of GC nucleotides, termed a GC clamp, 
as described in Chapter 7 of Erlich, supra. Preferably, at least 
80% of the nucleotides in the GC clamp are either guanine 
or cytosine. Preferably, the GC clamp is at least 30 bases 
long. This method is particularly suited to target sequences 
With high Tm’s. 
Generally, the target region is ampli?ed by the poly 
merase chain reaction as described above. One of the 
oligonucleotide PCR primers carries at its 5‘ end, the GC 
clamp region, at least 30 bases of the GC rich sequence, 
Which is incorporated into the 5‘ end of the target region 
during ampli?cation. The resulting ampli?ed target region is 
run on an electrophoresis gel under denaturing gradient 
conditions as described above. DNA fragments differing by 
a single base change Will migrate through the gel to different 
positions, Which may be visualiZed by ethidium bromide 
staining. 
Temperature Gradient Gel Electrophoresis 
Temperature gradient gel electrophoresis (TGGE) is 
based on the same underlying principles as denaturing 
gradient gel electrophoresis, except the denaturing gradient 
is produced by differences in temperature instead of differ 
ences in the concentration of a chemical denaturant. Stan 
dard TGGE utiliZes an electrophoresis apparatus With a 
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temperature gradient running along the electrophoresis path. 
As samples migrate through a gel With a uniform concen 
tration of a chemical denaturant, they encounter increasing 
temperatures. An alternative method of TGGE, temporal 
temperature gradient gel electrophoresis (TTGE or tTGGE) 
uses a steadily increasing temperature of the entire electro 
phoresis gel to achieve the same result. As the samples 
migrate through the gel the temperature of the entire gel 
increases, leading the samples to encounter increasing tem 
perature as they migrate through the gel. Preparation of 
samples, including PCR ampli?cation With incorporation of 
a GC clamp, and visualiZation of products are the same as 
for denaturing gradient gel electrophoresis. 
Single-strand Conformation Polymorphism Analysis 
Target sequences or alleles at the NRAMP1 locus can be 
differentiated using single-strand conformation polymor 
phism analysis, Which identi?es base differences by alter 
ation in electrophoretic migration of single stranded PCR 
products, as described in Orita et al., Proc. Nat. Acad. Sci. 
85:2766—2770 (1989). Ampli?ed PCR products can be gen 
erated as described above, and heated or otherWise 
denatured, to form single stranded ampli?cation products. 
Single-stranded nucleic acids may refold or form secondary 
structures Which are partially dependent on the base 
sequence. Thus, electrophoretic mobility of single-stranded 
ampli?cation products can detect base-sequence difference 
betWeen alleles or target sequences. 
Chemical or EnZymatic Cleavage of Mismatches 
Differences betWeen target sequences can also be detected 
by differential chemical cleavage of mismatched base pairs, 
as described in Grompe et al., Am. J. Hum. Genet. 
48:212—222 (1991). In another method, differences between 
target sequences can be detected by enZymatic cleavage of 
mismatched base pairs, as described in Nelson et al., Nature 
Genetics 4:11—18 (1993). Brie?y, genetic material from a 
patient and an affected family member may be used to 
generate mismatch free heterohybrid DNA duplexes. As 
used herein, “heterohybrid” means a DNA duplex strand 
comprising one strand of DNA from one person, usually the 
patient, and a second DNA strand from another person, 
usually an affected or unaffected family member. Positive 
selection for heterohybrids free of mismatches alloWs deter 
mination of small insertions, deletions or other polymor 
phisms that may be associated With alterations in androgen 
metabolism. 
Non-PCR Based DNA Diagnostics 
The identi?cation of a DNA sequence linked to NRAMP1 
can be made Without an ampli?cation step, based on poly 
morphisms including restriction fragment length polymor 
phisms in a patient and a family member. Hybridization 
probes are generally oligonucleotides Which bind through 
complementary base pairing to all or part of a target nucleic 
acid. Probes typically bind target sequences lacking com 
plete complementarity With the probe sequence depending 
on the stringency of the hybridiZation conditions. The probes 
are preferably labeled directly or indirectly, such that by 
assaying for the presence or absence of the probe, one can 
detect the presence or absence of the target sequence. Direct 
labeling methods include radioisotope labeling, such as With 
32P or 35S. Indirect labeling methods include ?uorescent 
tags, biotin complexes Which may be bound to avidin or 
streptavidin, or peptide or protein tags. Visual detection 
methods include photoluminescents, Texas red, rhodamine 
and its derivatives, red leuco dye and e, e‘, 5, 
5‘-5354amethylbenZidine (TMB), ?uorescein, and its 
derivatives, dansyl, umbelliferone and the like or With horse 
radish peroxidase, alkaline phosphatase and the like. 
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Hybridization probes include any nucleotide sequence 
capable of hybridizing to the porcine chromosome Where 
NRAMP1 resides, and thus de?ning a genetic marker linked 
to NRAMP, including a restriction fragment length 
polymorphism, a hypervariable region, repetitive element, 
or a variable number tandem repeat. HybridiZation probes 
can be any gene or a suitable analog. Further suitable 
hybridiZation probes include exon fragments or portions of 
cDNAs or genes knoWn to map to the relevant region of the 
chromosome. 
Preferred tandem repeat hybridiZation probes for use 
according to the present invention are those that recogniZe a 
small number of fragments at a speci?c locus at high 
stringency hybridiZation conditions, or that recogniZe a 
larger number of fragments at that locus When the stringency 
conditions are loWered. 
One or more additional restriction enZymes and/or probes 
and/or primers can be used. Additional enZymes, constructed 
probes, and primers can be determined by routine experi 
mentation by those of ordinary skill in the art and are 
intended to be Within the scope of the invention. 
Although the methods described herein may be in terms 
of the use of a single restriction enZyme and a single set of 
primers, the methods are not so limited. One or more 
additional restriction enZymes and/or probes and/or primers 
can be used, if desired. Additional enZymes, constructed 
probes and primers can be determined through routine 
experimentation, combined With the teachings provided and 
incorporated herein. 
Genetic markers for genes are determined as folloWs. 
Male and female animals of the same breed or breed cross 
or derived from similar genetic lineages are mated. The 
offspring With the bene?cial trait are determined. RFLP 
analysis of the parental DNA is conducted as discussed 
above in order to determine polymorphisms in the selected 
gene of each animal. The polymorphisms are associated With 
the traits. 
When this analysis is conducted and the polymorphism is 
determined by RFLP or other analysis, ampli?cation primers 
may be designed using analogous human or other closely 
related animal knoWn sequences. The sequences of many of 
the genes have high homology. Primers may also be 
designed using knoWn gene sequences as exempli?ed in 
Genbank or even designed from sequences obtained from 
linkage data from closely surrounding genes. According to 
the invention, sets of primers have been selected Which 
identify regions in polymorphic genes. The polymorphic 
fragments have been shoWn to be alleles, and each Was 
shoWn to be associated With bene?cial traits, such as disease 
resistance, for various breeds. Often genotype associated 
With this trait alternates for different breeds. This outcome is 
similar to the situation disclosed in US. Pat. No. 5,374,523 
entitled “Allelic variants of Bovine Somatotropin gene: 
Genetic marker for Superior Milk Production in Bovine” 
Where the inventor found an allelic polymorphism in the 
somatotropin gene and one allelic form Was bene?cial for 
jersey coWs and the alternate form Was bene?cial for Hol 
stein coWs. 
The reagents suitable for applying the methods of the 
invention may be packaged into convenient kits. The kits 
provide the necessary materials, packaged into suitable 
containers. At a minimum, the kit contains a reagent that 
identi?es a polymorphism in the selected gene that is 
associated With a trait. Preferably, the reagent is a PCR set 
(a set of primers, DNA polymerase and 4 nucleoside 
triphosphates) that hybridiZe With the gene or a fragment 
thereof. Preferably, the PCR set is included in the kit. 
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Preferably, the kit further comprises additional means, such 
as reagents, for detecting or measuring the detectable entity 
or providing a control. Other reagents used for 
hybridiZation, prehybridiZation, DNA extraction, visualiZa 
tion etc. may also be included, if desired. 
The methods and materials of the invention may also be 
used more generally to evaluate animal DNA, to identify 
analogous polymorphisms in animals other than those for 
Whom sequences have been disclosed herein, genetically 
type individual animals, and detect genetic differences in 
animals. 
In particular, a sample of genomic DNA may be evaluated 
by reference to one or more controls to determine if a 
polymorphism in the gene is present. Preferably, RFLP 
analysis is performed With respect to the gene, and the 
results are compared With a control. The control is the result 
of a RFLP analysis of the gene of a different animal Where 
the polymorphism of the gene is knoWn. Similarly, the 
genotype of an animal may be determined by obtaining a 
sample of its mRNA or genomic DNA, conducting RFLP 
analysis of the gene in the DNA, and comparing the results 
With a control. Again, the control is the result of RFLP 
analysis of the same gene of a different animal. The results 
genetically type the animal by specifying the polymorphism 
in its selected gene. Finally, genetic differences among 
animals can be detected by obtaining samples of the mRNA 
or genomic DNA from at least tWo animals, identifying the 
presence or absence of a polymorphism in the gene, and 
comparing the results. 
These assays are useful for identifying the genetic mark 
ers relating to disease resistance, as discussed above, for 
identifying other polymorphisms in the gene that may be 
correlated With other characteristics, and for the general 
scienti?c analysis of genotypes and phenotypes. 
The genetic markers, methods, and kits of the invention 
are also useful in a breeding program to improve disease 
resistance in a breed, line, or population of animals. Con 
tinuous selection and breeding of animals that are at least 
heteroZygous and preferably homoZygous for a polymor 
phism associated With a bene?cial trait such as disease 
resistance Would lead to a breed, line, or population having 
higher numbers of offspring in each litter of the females of 
this breed or line. Thus, the markers are selection tools. 
In another embodiment, the invention comprises a method 
for identifying a genetic marker for disease in a particular 
animal, species, or population. Male and female animals of 
the same breed or breed cross or similar genetic lineage are 
bred, and innate immunity of each pig is determined. A 
polymorphism in the NRAMP1 gene of each pig is identi?ed 
and associated With the innate immunity. Preferably, RFLP 
analysis is used to determine the polymorphism. 
In another embodiment, the invention comprises a method 
for identifying a genetic marker for disease resistance in any 
particular economic animal other than a pig. Based upon the 
highly conserved nature of this gene among different ani 
mals and the location of the polymorphisms Within these 
highly conserved regions, is it expected that With no more 
than routine testing as described herein this marker can be 
applied to different animal species to select for meat quality 
and/or groWth based on the teachings herein. Male and 
female animals of the same breed or breed cross or similar 
genetic lineage are bred, and the disease resistance of each 
animal is determined and correlated. For other animals in 
Which sequences are available a BLAST comparison of 
sequences may be used to ascertain Whether the particular 
allele is analogous to the one disclosed herein. The analo 
gous polymorphism Will be present in other animals and in 
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other closely related genes. The term “analogous polymor 
phism” shall be a polymorphism Which is the same as any of 
those disclosed herein as determined by BLAST compari 
sons. 
The following terms are used to describe the sequence 
relationships betWeen tWo or more nucleic acids or poly 
nucleotides: (a) “reference sequence”, (b) “comparison 
WindoW”, (c) “sequence identity”, (d) “percentage of 
sequence identity”, and (e) “substantial identity”. 
(a) As used herein, “reference sequence” is a de?ned 
sequence used as a basis for sequence comparison. In this 
case the Reference NRAMP1 sequence. A reference 
sequence may be a subset or the entirety of a speci?ed 
sequence; for example, as a segment of a full-length cDNA 
or gene sequence, or the complete cDNA or gene sequence. 
(b) As used herein, “comparison WindoW” includes ref 
erence to a contiguous and speci?ed segment of a poly 
nucleotide sequence, Wherein the polynucleotide sequence 
may be compared to a reference sequence and Wherein the 
portion of the polynucleotide sequence in the comparison 
WindoW may comprise additions or deletions (i.e., gaps) 
compared to the reference sequence (Which does not com 
prise additions or deletions) for optimal alignment of the tWo 
sequences. Generally, the comparison WindoW is at least 20 
contiguous nucleotides in length, and optionally can be 30, 
40, 50, 100, or longer. Those of skill in the art understand 
that to avoid a high similarity to a reference sequence due to 
inclusion of gaps in the polynucleotide sequence, a gap 
penalty is typically introduced and is subtracted from the 
number of matches. 
Methods of alignment of sequences for comparison are 
Well-known in the art. Optimal alignment of sequences for 
comparison may be conducted by the local homology algo 
rithm of Smith and Waterman, Adv. Appl. Math. 2:482 
(1981); by the homology alignment algorithm of Needleman 
and Wunsch, J. Mol. Biol. 48:443 (1970); by the search for 
similarity method of Pearson and Lipman, Proc. Natl. Acad. 
Sci. 8512444 (1988); by computeriZed implementations of 
these algorithms, including, but not limited to: CLUSTAL in 
the PC/Gene program by Intelligenetics, Mountain VieW, 
Calif.; GAP, BESTFIT, BLAST, FASTA, and TFASTA in the 
Wisconsin Genetics SoftWare Package, Genetics Computer 
Group (GCG), 575 Science Dr., Madison, Wis., USA; the 
CLUSTAL program is Well described by Higgins and Sharp, 
Gene 73:237—244 (1988); Higgins and Sharp, CABIOS 
5:151—153 (1989); Corpet, et al., Nucleic Acids Research 
16:10881—90 (1988); Huang, et al., Computer Applications 
in the Biosciences 8:155—65 (1992), and Pearson, et al., 
Methods in Molecular Biology 24:307—331 (1994). The 
BLAST family of programs Which can be used for database 
similarity searches includes: BLASTN for nucleotide query 
sequences against nucleotide database sequences; BLASTX 
for nucleotide query sequences against protein database 
sequences; BLASTP for protein query sequences against 
protein database sequences; TBLASTN for protein query 
sequences against nucleotide database sequences; and 
TBLAST'X for nucleotide query sequences against nucle 
otide database sequences. See, Current Protocols in Molecu 
lar Biology, Chapter 19, Ausubel, et al., Eds., Greene 
Publishing and Wiley-Interscience, NeW York (1995). 
Unless otherWise stated, sequence identity/similarity val 
ues provided herein refer to the value obtained using the 
BLAST 2.0 suite of programs using default parameters. 
Altschul et a., Nucleic Acids Res. 25:3389—3402 (1997). 
SoftWare for performing BLAST analyses is publicly 
available, e.g., through the National Center for 
Biotechnology-Information (WWW.ncbi.nlm.nih.gov/). 
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This algorithm involves ?rst identifying high scoring 
sequence pairs (HSPs) by identifying short Words of length 
W in the query sequence, Which either match or satisfy some 
positive-valued threshold score T When aligned With a Word 
of the same length in a database sequence. T is referred to 
as the neighborhood Word score threshold (Altschul et al., 
supra). These initial neighborhood Word hits act as seeds for 
initiating searches to ?nd longer HSPs containing them. The 
Word hits are then extended in both directions along each 
sequence for as far as the cumulative alignment score can be 
increased. Cumulative scores are calculated using, for nucle 
otide sequences, the parameters M (reWard score for a pair 
of matching residues; alWays >0) and N (penalty score for 
mismatching residues; alWays <0). For amino acid 
sequences, a scoring matrix is used to calculate the cumu 
lative score. Extension of the Word hits in each direction are 
halted When: the cumulative alignment score falls off by the 
quantity X from its maximum achieved value; the cumula 
tive score goes to Zero or beloW, due to the accumulation of 
one or more negative-scoring residue alignments; or the end 
of either sequence is reached. The BLAST algorithm param 
eters W, T, and X determine the sensitivity and speed of the 
alignment. The BLASTN program (for nucleotide 
sequences) uses as defaults a Wordlength of 11, an 
expectation of 10, a cutoff of 100, M=5, N=—4, and a 
comparison of both strands. For amino acid sequences, the 
BLASTP program uses as defaults a Wordlength of 3, an 
expectation of 10, and the BLOSUM62 scoring matrix 
(see Henikoff & Henikoff (1989) Proc. Natl. Acad. Sci. USA 
89110915). 
In addition to calculating percent sequence identity, the 
BLAST algorithm also performs a statistical analysis of the 
similarity betWeen tWo sequences (see, e.g., Karlin & 
Altschul, Proc. Natl. Acad. Sci. USA 90:5873—5787 (1993)). 
One measure of similarity provided by the BLAST algo 
rithm is the smallest sum probability (P(N)), Which provides 
an indication of the probability by Which a match betWeen 
tWo nucleotide or amino acid sequences Would occur by 
chance. 
BLAST searches assume that proteins can be modeled as 
random sequences. HoWever, many real proteins comprise 
regions of nonrandom sequences Which may be homopoly 
meric tracts, short-period repeats, or regions enriched in one 
or more amino acids. Such loW-complexity regions may be 
aligned betWeen unrelated proteins even though other 
regions of the protein are entirely dissimilar. A number of 
loW-complexity ?lter programs can be employed to reduce 
such loW-complexity alignments. For example, the SEG 
(Wooten and Federhen, Comput. Chem., 17:149—163 
(1993)) and XNU (Claverie and States, Comput. Chem., 
17: 191—201 (1993)) loW-complexity ?lters can be employed 
alone or in combination. 
(c) As used herein, “sequence identity” or “identity” in the 
context of tWo nucleic acid or polypeptide sequences 
includes reference to the residues in the tWo sequences 
Which are the same When aligned for maximum correspon 
dence over a speci?ed comparison WindoW. When percent 
age of sequence identity is used in reference to proteins it is 
recogniZed that residue positions Which are not identical 
often differ by conservative amino acid substitutions, Where 
amino acid residues are substituted for other amino acid 
residues With similar chemical properties (eg charge or 
hydrophobicity) and therefore do not change the functional 
properties of the molecule. Where sequences differ in con 
servative substitutions, the percent sequence identity may be 
adjusted upWards to correct for the conservative nature of 
the substitution. Sequences Which differ by such conserva 
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tive substitutions are said to have “sequence similarity” or 
“similarity”. Means for making this adjustment are Well 
knoWn to those of skill in the art. Typically this involves 
scoring a conservative substitution as a partial rather than a 
full mismatch, thereby increasing the percentage sequence 
identity. Thus, for example, Where an identical amino acid is 
given a score of 1 and a non-conservative substitution is 
given a score of Zero, a conservative substitution is given a 
score betWeen Zero and 1. The scoring of conservative 
substitutions is calculated, e.g., according to the algorithm of 
Meyers and Miller, Computer Applic. Biol. Sci., 4:11—17 
(1988) e.g., as implemented in the program PC/GENE 
(Intelligenetics, Mountain VieW, Calif., USA). 
(d) As used herein, “percentage of sequence identity” 
means the value determined by comparing tWo optimally 
aligned sequences over a comparison WindoW, Wherein the 
portion of the polynucleotide sequence in the comparison 
WindoW may comprise additions or deletions (i.e., gaps) as 
compared to the reference sequence (Which does not com 
prise additions or deletions) for optimal alignment of the tWo 
sequences. The percentage is calculated by determining the 
number of positions at Which the identical nucleic acid base 
or amino acid residue occurs in both sequences to yield the 
number of matched positions, dividing the number of 
matched positions by the total number of positions in the 
WindoW of comparison and multiplying the result by 100 to 
yield the percentage of sequence identity. 
(e) (I) The term “substantial identity” of polynucleotide 
sequences means that a polynucleotide comprises a 
sequence that has at least 70% sequence identity, preferably 
at least 80%, more preferably at least 90% and most pref 
erably at least 95%, compared to a reference sequence using 
one of the alignment programs described using standard 
parameters. One of skill Will recogniZe that these values can 
be appropriately adjusted to determine corresponding iden 
tity of proteins encoded by tWo nucleotide sequences by 
taking into account codon degeneracy, amino acid similarity, 
reading frame positioning and the like. Substantial identity 
of amino acid sequences for these purposes normally means 
sequence identity of at least 60%, or preferably at least 70%, 
80%, 90%, and most preferably at least 95%. 
These programs and algorithms can ascertain the analogy 
of a particular polymorphism in a target gene to those 
disclosed herein. It is expected that this polymorphism Will 
exist in other animals and use of the same in other animals 
than disclosed herein involved no more than routine opti 
miZation of parameters using the teachings herein. 
It is also possible to establish linkage betWeen speci?c 
alleles of alternative DNA markers and alleles of DNA 
markers knoWn to be associated With a particular gene (eg 
the NRAMP1 gene discussed herein), Which have previ 
ously been shoWn to be associated With a particular trait. 
Thus, in the present situation, taking the NRAMP1 gene, it 
Would be possible, at least in the short term, to select for pigs 
likely to produce desired meat quality and/or groWth, or 
alternatively against pigs likely to produce less desirable 
meat quality and/or groWth, indirectly, by selecting for 
certain alleles of a NRAMP1 associated marker through the 
selection of speci?c alleles of alternative chromosome mark 
ers. As used herein the term “genetic marker” shall include 
not only the polymorphism disclosed by any means of 
assaying for the protein changes associated With the 
polymorphism, be they linked markers, use of 
microsatellites, or even other means of assaying for the 
causative protein changes indicated by the marker and the 
use of the same to in?uence the meat quality and/or groWth 
of an animal. 
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As used herein, often the designation of a particular 
polymorphism is made by the name of a particular restric 
tion enZyme. This is not intended to imply that the only Way 
that the site can be identi?ed is by the use of that restriction 
enZyme. There are numerous databases and resources avail 
able to those of skill in the art to identify other restriction 
enZymes Which can be used to identify a particular 
polymorphism, for example WWW.darWin.bio.geneseo.edu 
Which can give restriction enZymes upon analysis of a 
sequence and the polymorphism to be identi?ed. In fact as 
disclosed in the teachings herein there are numerous Ways of 
identifying a particular polymorphism or allele With alter 
nate methods Which may not even include a restriction 
enZyme, but Which assay for the same genetic or proteomic 
alternative form. 
In yet another embodiment of this invention novel porcine 
nucleotide sequences have been identi?ed and are disclosed 
Which encode porcine NRAMP1. The cDNA of the porcine 
NRAMP1 gene as Well as some intronic DNA sequences are 
disclosed. These sequences may be used for the design of 
primers to assay for the SNP’s of the invention or for 
production of recombinant NRAMP1. The invention is 
intended to include these sequences as Well as all conser 
vatively modi?ed variants thereof as Well as those sequences 
Which Will hybridiZe under conditions of high stringency to 
the sequences disclosed. The term NRAMP1 as used herein 
shall be interpreted to include these conservatively modi?ed 
variants as Well as those hybridiZed sequences. 
The term “conservatively modi?ed variants” applies to 
both amino acid and nucleic acid sequences. With respect to 
particular nucleic acid sequences, conservatively modi?ed 
variants refers to those nucleic acids Which encode identical 
or conservatively modi?ed variants of the amino acid 
sequences. Because of the degeneracy of the genetic code, a 
large number of functionally identical nucleic acids encode 
any given protein. For instance, the codons GCA, GCC, 
GCG and GCU all encode the amino acid alanine. Thus, at 
every position Where an alanine is speci?ed by a codon, the 
codon can be altered to any of the corresponding codons 
described Without altering the encoded polypeptide. Such 
nucleic acid variations are “silent variations” and represent 
one species of conservatively modi?ed variation. Every 
nucleic acid sequence herein that encodes a polypeptide 
also, by reference to the genetic code, describes every 
possible silent variation of the nucleic acid. One of ordinary 
skill Will recogniZe that each codon in a nucleic acid (except 
AUG, Which is ordinarily the only codon for methionine; 
and UGG, Which is ordinarily the only codon for tryptophan) 
can be modi?ed to yield a functionally identical molecule. 
Accordingly, each silent variation of a nucleic acid Which 
encodes a polypeptide of the present invention is implicit in 
each described polypeptide sequence and is Within the scope 
of the present invention. 
As to amino acid sequences, one of skill Will recogniZe 
that individual substitutions, deletions or additions to a 
nucleic acid, peptide, polypeptide, or protein sequence 
Which alters, adds or deletes a single amino acid or a small 
percentage of amino acids in the encoded sequence is a 
“conservatively modi?ed variant” Where the alteration 
results in the substitution of an amino acid With a chemically 
similar amino acid. Thus, any number of amino acid residues 
selected from the group of integers consisting of from 1 to 
15 can be so altered. Thus, for example, 1, 2, 3, 4, 5, 7, or 
10 alterations can be made. Conservatively modi?ed vari 
ants typically provide similar biological activity as the 
unmodi?ed polypeptide sequence from Which they are 
derived. For example, substrate speci?city, enZyme activity, 
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or ligand/receptor binding is generally at least 30%, 40%, 
50%, 60%, 70%, 80%, or 90% of the native protein for its 
native substrate. Conservative substitution tables providing 
functionally similar amino acids are Well knoWn in the art. 
The following six groups each contain amino acids that 
are conservative substitutions for one another: 
1) Alanine (A), Serine (S), Threonine (T); 
2) Aspartic acid (D), Glutamic acid 
3) Asparagine (N), Glutamine (Q); 
4) Arginine (R), Lysine 
5) Isoleucine (I), Leucine (L), Methionine (M), Valine 
(V); and 
6) Phenylalanine (F), Tyrosine (Y), Tryptophan See also, Creighton (1984) Proteins W. H. Freeman and 
Company. 
By “encoding” or “encoded”, With respect to a speci?ed 
nucleic acid, is meant comprising the information for trans 
lation into the speci?ed protein. A nucleic acid encoding a 
protein may comprise non-translated sequences (e.g., 
introns) Within translated regions of the nucleic acid, or may 
lack such intervening non-translated sequences (e.g., as in 
cDNA). The information by Which a protein is encoded is 
speci?ed by the use of codons. Typically, the amino acid 
sequence is encoded by the nucleic acid using the “univer 
sal” genetic code. HoWever, variants of the universal code, 
such as are present in some plant, animal, and fungal 
mitochondria, the bacterium M ycoplasma capricolum, or the 
ciliate Macronucleus, may be used When the nucleic acid is 
expressed therein. 
The term “stringent conditions” or “stringent hybridiZa 
tion conditions” includes reference to conditions under 
Which a probe Will hybridiZe to its target sequence, to a 
detectably greater degree than to other sequences (e.g., at 
least 2-fold over background). Stringent conditions are 
sequence-dependent and be different in different circum 
stances. By controlling the stringency of the hybridiZation 
and/or Washing conditions, target sequences can be identi 
?ed Which are 100% complementary to the probe 
(homologous probing). Alternatively, stringency conditions 
can be adjusted to alloW some mismatching in sequences so 
that loWer degrees of similarity are detected (heterologous 
probing). Generally, a probe is less than about 1000 nucle 
otides in length, optionally less than 500 nucleotides in 
length. 
Typically, stringent conditions Will be those in Which the 
salt concentration is less than about 1.5 M Na ion, typically 
about 0.01 to 1.0 M Na ion concentration (or other salts) at 
pH 7.0 to 8.3 and the temperature is at least about 30° C. for 
short probes (e.g., 10 to 50 nucleotides) and at least about 
60° C. for long probes (e.g., greater than 50 nucleotides). 
Stringent conditions may also be achieved With the addition 
of destabiliZing agents such as formamide. Exemplary loW 
stringency conditions include hybridiZation With a buffer 
solution of 30 to 35% formamide, 1 M NaCl, 1% SDS 
(sodium dodecyl sulphate) at 37° C., and a Wash in 1x to 2x 
SSC (20>< SSC=3.0 M NaCl/0.3 M trisodium citrate) at 50 
to 55° C. Exemplary moderate stringency conditions include 
hybridiZation in 40 to 45% formamide, 1 M NaCl, 1% SDS 
at 37° C., and a Wash in 0.5>< to 1x SSC at 55 to 50° C. 
Exemplary high stringency conditions include hybridiZation 
in 50% formamide, 1 M NaCl, 1% SDS at 37° C., and a Wash 
in 0.1>< SSC at 60 to 65° C. 
Speci?city is typically the function of post-hybridiZation 
Washes, the critical factors being the ionic strength and 
temperature of the ?nal Wash solution. For DNA-DNA 
hybrids, the Tm can be approximated from the equation of 
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Meinkoth and Wahl, Anal. Biochem., 138:267—284 (1984): 
Tm=81.5° C.+16.6 (log M)+0.41 (% GC)—0.61 (% form) 
500/L; Where M is the molarity of monovalent cations, %GC 
is the percentage of guanosine and cytosine nucleotides in 
the DNA, % form is the percentage of formamide in the 
hybridiZation solution, and L is the length of the hybrid in 
base pairs. The Tm is the temperature (under de?ned ionic 
strength and pH) at Which 50% of the complementary target 
sequence hybridiZes to a perfectly matched probe. Tm is 
reduced by about 1° C. for each 1% of mismatching; thus, 
Tm, hybridiZation and/or Wash conditions can be adjusted to 
hybridiZe to sequences of the desired identity. For example, 
if sequences With 290% identity are sought, the Tm can be 
decreased 10° C. Generally, stringent conditions are selected 
to be about 5° C. loWer than the thermal melting point (Tm) 
for the speci?c sequence and its complement at a de?ned 
ionic strength and pH. HoWever, severely stringent condi 
tions can utiliZe a hybridiZation and/or Wash at 1, 2, 3, or 4° 
C. loWer than the thermal melting point (Tm); moderately 
stringent conditions can utiliZe a hybridiZation and/or Wash 
at 6, 7, 8, 9, or 10° C. loWer than the thermal melting point 
(Tm); loW stringency conditions can utiliZe a hybridiZation 
and/or Wash at 11, 12, 13, 14, 15, or 20° C. loWer than the 
thermal melting point (Tm). Using the equation, hybridiZa 
tion and Wash compositions, and desired Tm, those of 
ordinary skill Will understand that variations in the strin 
gency of hybridiZation and/or Wash solutions are inherently 
described. If the desired degree of mismatching results in a 
Tm of less than 45° C. (aqueous solution) or 32° C. 
(formamide solution) it is preferred to increase the SSC 
concentration so that a higher temperature can be used. An 
extensive guide to the hybridization of nucleic acids is found 
in Tijssen, Laboratory Techniques in Biochemistry and 
Molecular Biology-Hybridization With Nucleic Acids 
Probes, Part I, Chapter 2, Ausubel, et al., Eds., Greene 
Publishing and Wiley-Interscience, NeW York (1995). 
The examples and methods herein disclose certain genes 
Which have been identi?ed to have a polymorphism Which 
is associated either positively or negatively With a bene?cial 
trait that Will have an effect on disease resistance of that 
animal. The identi?cation of the existence of a polymor 
phism Within a gene is often made by a single base alter 
native that results in a restriction site in certain allelic forms. 
A certain allele, hoWever, as demonstrated and discussed 
herein, may have a number of base changes associated With 
it that could be assayed for Which are indicative of the same 
polymorphism. Further, other genetic markers or genes may 
be linked to the polymorphisms disclosed herein so that 
assays may involve identi?cation of other genes or gene 
fragments, but Which ultimately rely upon genetic charac 
teriZation of animals for the same polymorphism. Any assay 
Which sorts and identi?es animals based upon the allelic 
differences disclosed herein are intended to be included 
Within the scope of this invention. 
One of skill in the art, once a polymorphism has been 
identi?ed and a correlation to a particular trait established, 
Will understand that there are many Ways to genotype 
animals for this polymorphism. The design of such alterna 
tive tests merely represent optimiZation of parameters 
knoWn to those of skill in the art and are intended to be 
Within the scope of this invention as fully described herein. 
According to the invention ?ve different marker systems 
have been identi?ed in the porcine NRAMP1 gene Which are 
associated With innate immunity traits. One polymorphism 
has been previously disclosed, hoWever, no association With 
any phenotypic trait has ever been reported; the remaining 
four are novel polymorphisms. Of the four markers, one is 
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in exon 15, one in the region of exon/intron 2—3, one in the 
promoter region and one is in intron 1. Novel NRAMP1 
sequence has been identi?ed as Well as exemplary primers 
for assaying for the polymorphisms. The markers are asso 
ciated With innate immunity traits Which are non-pathogen 
speci?c, so While bacteria is used for challenge it is expected 
that these traits Will improve animal health against a Wide 
variety of diseases or challenges such as stress, viral 
pathogen, etc. The porcine NRAMP1 cDNA is disclosed in 
Tuggle et al., “Rapid Communication: Cloning of a Pig 
Full-Length Natural Resistance Associated Macrophage 
Protein (NRAMP1) cDN ”, J. Anim. Sci. 75:277 (1997). 
Also disclosed herein are novel primer sequences, hoWever 
those of skill in the art Will readily be able to design a 
multitude of alternative primers to amplify the region of the 
polymorphism using the sequence data already knoWn in the 
art and are available in sources such as Genbank and 
disclosed herein. A different marker system, using primers 
that amplify from exon 1—3 and using the HinfI enZyme to 
detect polymorphic sequences Within this region, is dis 
closed in Sun, H. S., et al., “Mapping of the natural 
resistance-associated macrophage protein 1 (NRAMP1) 
gene to pig chromosome 15”, Animal Genetics 29:138—140 
(1998). Only the polymorphism test (not the speci?c 
sequence differences creating the polymorphic restriction 
fragment length polymorphism), and a method to detect 
such polymorphisms using HinfI enZyme, Were disclosed by 
Sun et al. Also disclosed herein is an association of geno 
types detectable by the HinfI marker With innate immunity 
traits. 
The ?rst marker system is located in the exon/intron 2—3 
region and detects 4 alleles produced from A to G or G to A 
transitions at the positions shoWn in FIG. 1 (SEQ ID NO:3). 
For example, using novel primers SEQ ID NO:1 and SEQ 
ID NO:2 a novel 536 bp sequence, Which spans part of intron 
2, all of exon 2 and part of intron 3 of the porcine NRAMP1 
gene as shoWn in FIG. 1, can be ampli?ed. FIG. 1 shoWs the 
DNA sequence of the 536 bp PCR product (SEQ ID NO:3). 
The primer regions are shoWn in bold text, and exon 2 is in 
italic text. The polymorphic sequences detected With an 
enZyme like AvaII are underlined While the polymorphic 
sequences detected With an enZyme like HinfI are double 
underlined (R=A or G; Y=C or T). 
PCR Primers 
GCGTCAGTCTTCCCTGCTCAG SEQ ID NO: 1 
ACGGCAGTTACCACTCTCCATCT SEQ ID NO:2 
PCR Conditions 
PCR Was performed in 10 pl reactions including 1><PCR 
buffer, 1.5 mM MgCl2, 0.2 mM dNTPs, 3 pmol of each 
primer and 0.38 U of Taq polymerase. 
PCR program: 
1 x 95° C. 2 min, 
40 x: 95° C. 45 sec 
62° C. 45 sec 
72° C. 90 sec 
1 x 72° C. 5 min 
The A/G transitions can be identi?ed by a restriction 
enZyme such as Ava II resulting in the folloWing alleles: 
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Allele Position" 72 Position 364 Fragments 
1 G A 411, 72, 53 
2 G G 291, 120, 72, 53 
3 A A 483, 53 
4 A G 363, 120, 53 
*position is calculated based upon 536 bp ampli?ed fragment (SEQ ID 
NO: 5) All alleles cut at position 53. These alleles can easily be correlated 
With NRAMP1 sequences disclosed herein and based upon the teachings 
herein to identify other primers or methods of identi?cation. 
By using an enZyme like HinfI and the above 536 bp PCR 
product, the previously disclosed polymorphism (Sun et al 
1998) can also be more easily detected due to the fact that 
the 536 bp PCR product can amplify this region in a more 
robust manner With more pig DNA samples than the tech 
nology reported in the Sun et al 1998 publication. BeloW is 
also disclosed novel sequence differences causing the HinfI 
RFLP Which Were not disclosed in the Sun et al 1998 
publication. 
Thus either the AvaII or the HinfI enZyme can be used for 
detecting polymorphisms Within the 536 bp PCR product. 
Alleles Detected by Digestion With an EnZyme Like HinfI 
Allele Position" 176 Position 331 Fragments 
A G C 360, 100, 76 
B G T 205, 155, 100, 76 
C A T 231, 205, 100 
*position is calculated based upon 536 ampli?ed fragment (SEQ ID NO: 
5) All alleles cut at position 100. These alleles can easily be correlated 
With NRAMP1 sequences disclosed herein and upon the teachings herein 
to identify other primers or methods of identi?cation. 
For the second novel marker system 2 alleles are detected 
in exon 14—15, again With A<:>G transitions. Allele 4 has an 
A at position 473 of the 615 bp ampli?ed product (With SEQ 
ID NOS: 5 and 6 primers) and allele 5 has a G at position 
473. 
NRAMP1 MspA1I Marker(SEQ ID NO:4) 
Primers 
CATGCTGCTGGTCTGTGCC (SEQ ID NO:5) 
ATTGCAAGATTGGTGTTGTCCC (SEQ ID NO:6) 
The sequence of PCR product is shoWn in FIG. 2, Which 
is DNA sequence of the 615 bp PCR product (SEQ ID 
NO:4). The primer regions are shoWn in bold text, the 
polymorphic MspAI site is underlined and intron 14 is in 
italic text. 
Restriction Fragment Detected With MspA1I 
Fragments 142bp (both alleles) 
473bp (allele 4) 
152bp and 321bp (allele 5) 
R = A or G 
Allele 4=A at position 473; Allele 5=G at position 473. 
PCR Conditions 
PCR Was performed in 15 pl reactions including 
1><PCRbuffer, 1.5 mM MgCl2, 0.17 mM dNTPs, 4 pmol of 
each primer and 1 U of Taq polymerase. 
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PCR Program: 
1><(95° C. 1 min) 
31><(95° C. 30 s, 56° C. 1 min, 72° C. 1 min) 
1><(72° C. 5 min) 
For the third and fourth novel marker systems, tWo 
different sets of polymorphisms are found using tWo differ 
ent enzymes digesting the same 934 bp PCR product. 
In the third marker system, 2 alleles are detected in intron 
1, using the SmaI enZyme, again With ASG transitions. 
Allele 6 (determined by SmaI digestion of the PCR product) 
has a G at position 737 of the 934 bp PCR product, While 
Allele 7 (determined by SmaI digestion of the PCR product) 
has an A at position 737. 
In the fourth marker system, 2 alleles are detected in the 
promoter region, using the NlaIII enZyme, again With A<:>G 
transitions. Allele 8 (determined by NlaIII digestion of the 
PCR product) has a G at position 310 of the 934 bp PCR 
product, While Allele 9 (determined by NlaIII digestion of 
the PCR product) has an A at position 310. 
5‘UTR NRAMP1 PCR product of 934 bp: (SEQ ID NO:7) 
5‘ UTR NRAMP1 PCR primers: 
ForWard Primer name: NR1 (SEQ ID NO:8) 
5‘ TGA RCY CTT CAT TTA ACA GAA GA 3‘ 
Reverse Primer name: NR942 (SEQ ID NO: 9) 
5‘ GGC TCT GAG CAG GGA AGA CT 3‘ 
PCR Conditions 
Mg++conc 2.5 mM, dNTPs-conc 200.0 nM, Taq 0.375U 
Cycle pro?le 94C. for 3 min; 35><[94c for 45 s; 59.3C. for 
45 s; 72C. for 1 min] 72C. for 10 min. 
PCR-Annotation 
Ampli?cation Was performed using 25 ng of genomic 
DNA and 0.3 nM of each primer (10 pmol/ul) in a reaction 
volume of 10 pl. 
FIG. 3 is the sequence of 934 bp PCR product (ampli?es 
5‘UTR to intron 1): 
The tWo polymorphic sites are underlined (R=A or G). 
Primer sequences are in bold, With the reverse complement 
of the 3‘ primer shoWn. 
SmaI Digestion 
Digestion miX: Per sample to be digested, a miX Was 
prepared consisting of 2 ul of 10x J buffer (Promega, Inc), 
8 U of SmaI enZyme (Promega, Inc) in a ?nal volume of 14 
ul. To each 6 uL PCR product, add 14 uL digestion miX and 
incubate With oil overnight at room temp. Check digestion 
pattern on a 2% agarose gel. 
EXpected Band SiZes: 
Allele 6: 505bp, 232bp, 198 bp 
Allele 7: 505bp, 430bp 
NlaIII Digestion 
Digestion miX: Per sample to be digested, a miX Was 
prepared consisting of 1.5 ul of 10><NEB4 buffer (NeW 
England Biolabs, Inc.), 6 U of NlaIII enZyme (NeW England 
Biolabs, Inc) and 1.5 ug bovine serum albumin in a ?nal 
volume of 10.5 ul. To each 4.5 uL PCR product, add 10.5 uL 
digestion miX and incubate With oil overnight at 37 C. Check 
digestion pattern on a 2% agarose gel. 
EXpected Band SiZes: 
Allele 8: 310 bp, 281 bp, 142 bp, 75 bp, 71 bp, 56 bp 
Allele 9: 281 bp, 200 bp, 142 bp, 110 bp, 75 bp, 71 bp, 56 
bp 
EXAMPLE 1 
Bacterial Challenge and Association Testing 
Summary 
To test the utility of the marker tests to identify animals 
differing for innate immunity traits, tWo batches of pigs Were 
experimentally challenged With Salmonella cholerasuis and 
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infection related measurements Were taken post infection. 
NRAMP1 polymorphisms Were genotyped in the challenged 
animals. Association analysis revealed statistically signi? 
cant effects of NRAMP1 genotype on fecal bacteria counts, 
as Well as several measures of immune cell numbers, during 
the challenge. Controlling fecal bacterial counts has eco 
nomic value as an infected animal is the main source of 
transmission of the disease to healthy animals. Thus a 
marker that Would identify animals With decreased fecal 
bacterial counts Would be valuable and have utility. 
Pregnant soWs Were pre-selected based on data from 
preliminary NRAMP1 genotype analysis and a crude in vitro 
macrophage bactericidal assay results. From these soWs, tWo 
separate experiments of 42 piglets (8—19 days old) Were 
derived and piglets shipped to isolation facilities. Piglets 
consisted of 2 lines of pigs from tWo different farms. Piglets 
Were determined to be Salmonella-free by frequent bacterial 
culture of fecal material. Piglets Were divided into principals 
and controls and groWn to 7—9 Weeks of age prior to 
intranasal challenge With 1 billion colony forming units of 
Salmonella choleraesuis X3246. The control group (saline 
inoculated) consisted of 1 piglet/litter (EXp #1, n=13; EXp 
#2, n=12). The principal group (Salmonella infected) con 
sisted of 2 or 3 piglets/litter (EXp #1, n=29; EXp #2, n=30). 
FolloWing challenge, animals Were monitored daily for 
temperature, clinical signs and Salmonella shedding 
(qualitative and quantitative). Pigs Were necropsied post S. 
choleraesuis or saline inoculation and quantitative bacteri 
ology (most probable number) Was performed on ileocecal 
lymph node and from fecal samples at the end of the 
challenge. Blood samples taken before challenge and at 
necropsy Were used to assess immune cell numbers and 
response to infection. Portions of mesenteric lymph node, 
spleen, liver, lung, and muscle Were collected and froZen in 
liquid nitrogen for DNA analysis. Piglets Were also geno 
typed by using several NRAMP1 marker systems described 
above. Results are shoWn in Tables 1—5, and genotype 
frequencies Within this challenge population for each of the 
markers is shoWn in Table 6. 
Statistical Treatment of Data Within Line Analysis 
Multiallelic Markers 
For markers With more than 2 alleles (NRAMP1-HinfI 
and NRAMP1-AvaII) the folloWing miXed model Was used 
to estimate the contrast of each allele With all the others 
combined (1—all, 2—all, etc.). These are therefore indi 
vidual allele substitution effects. The eXpected difference 
betWeen a “1/1” genotype and a “not-1/not-1” genotype is 
tWo times the allele substitution effect. General linear mod 
els Were used: 
Trait=soWid+eXperiment+barn+allele1+allele2+allele3 (+allele 4 
for NRAMP1-AvaII). 
With soWid as random effect and eXperiment and barn as 
?Xed effects. Signi?cance p-values for each of the allele 
substitution effects Were recorded from this model. 
Bi-allelic Markers 
For markers With 2 alleles Least square means (LS means) 
With standard errors (s.e.) Were estimated for the 3 genotype 
classes from the folloWing model: 
Trait=soWid+eXperiment+barn+genotype 
With soWid as random effect and eXperiment and barn as 
?Xed effects. Signi?cant p-values for genotype comparisons 
Were also recorded from this model. 
Analysis Across Lines 
The same models Were used for the across lines analyses 
as described for the Within line analyses With the only 
difference that a ?Xed effect for line Was added. 
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Results and Discussion 
Overall results are summarized in the following tables. 
The data Were log transformed for the following traits: all 
bacterial counts as Well as macrol, macro2, mono2 and 
Wbc1, because of the non-normal distribution of the data, a 
Widely accepted treatment for non-normally distributed data 
sets. 
As can be seen from the data, NRAMP1 genotypes are 
associated With differences in fecal bacterial counts 
(FMPND6; fecal bacterial count on day 6 of challenge), and 
that this is seen in one or both lines and/or in the combined 
samples for every marker system. Some alleles are found to 
be associated With FMPND6 in only one of the analyses, 
often due to lack of informativeness of the marker. 
Also shoWn by the data are NRAMP1 genotypes that are 
associated With several innate immune defense measures. 
These parameters are critical for control of and recovery 
from infection, and include fever (temperature) and numbers 
of immune cells (i.e. White blood cells, lymphocytes, 
neutrophils, monocytes) before and after infection. As 
above, some alleles are found to be associated With innate 
immune traits in only one of the analyses, often due to lack 
of informativeness of the marker. 
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TABLE 1 
NRAMP1 Hinf1 genotype association 
analysis in example 1. 
Allele substitution effects 
Line B 
1-all 2-all 3-all 
TRAITa Effect P value Effect P value Effect P value 
TempD0 0.03 0.81 —0.04 0.63 0.01 0.96 
TempDl —0.13 0.47 0.22 0.06 —0.09 0.61 
TempD2 —0.31 0.19 0.11 0.47 0.20 0.39 
TempD3 —0.18 0.42 —0.27 0.05 0.45 0.04 
TempD4 0.24 0.29 —0.18 0.23 —0.07 0.77 
TempD6 —0.40 0.07 0.16 0.27 0.24 0.27 
TempD7 —0.43 0.06 0.22 0.13 0.21 0.34 
FMPND6 0.81 0.17 0.27 0.43 —1.09 0.06 
lymphidiff 1.77 0.06 —0.60 0.30 —1.16 0.18 
pneut2 3.48 0.52 —6.31 0.08 2.83 0.62 
aTraits are: 
TEMPDO = temperature on day 0 of challenge, 
TEMPD1 — temperature on day 1 after challenge, etc.; 
FMPND6 = mean fecal Salmonella count on day 6 after challenge; 
lymphidiff = difference in blood lymphocyte numbers between days 0 
and 7 after challenge; 
pneut2 = percentage of blood neutrophils after challenge. 
TABLE 2a 
NRAMP1 Ava11 genotype association 
analysis in example 1. 
Allele substitution effects (p value) 
LineA Line B 
TRAIT‘i 1-all 2-all 3-all 4-all 1-all 2-all 3-all 4-all 
TempD0 .04 (.77) —.10 (.64) —.86 (.13) .92 (.11) .05 (.55) .03 (.69) —.08 (.34) — 
TempDl —.06 (.59) —.02 (.88) —.33 (.43) .41 (.30) .25 (.02) —.08 (.41) —.17 (.10) — 
TempD2 —.01 (.96) —.07 (.79) —.42 (.69) .50 (.58) .06 (.71) —.10 (.50) .04 (.82) — 
TempD3 .25 (.31) —.06 (.81) .10 (.91) —.30 (.72) .13 (.28) .17 (.11) —.30 (.02) — 
TempD4 —.22 (.47) —.52 (.27) — .74 (.29) —.15 (.33) .005 (.97) .14 (.34) — 
TempD6 —.001 (.74) .002 (.59) —.002 (.83) .001 (.91) 0 (.63) 0 (.98) 0 (.64) — 
TempD7 —.29 (.21) .48 (.07) .46 (.59) —.65 (.40) .18 (.33) —.004 (.98) —.17 (.34) — 
FMPND1 —1.4 (.04) —.44 (.30) 4.1 (.03) —2.2 (.13) —.22 (.51) .11 (.66) .11 (.67) — 
FMPND6 —.33 (.64) —.69 (.48) —.59 (.81) 1.6 (.51) —.47 (.08) —.10 (.69) .56 (.02) — 
Macro1 .11 (.34) .27 (.07) —.64 (.22) .25 (.53) .03 (.59) .04 (.34) —.06 (.17) — 
Macro2 .03 (.75) —.08 (.49) —.38 (.38) .42 (.28) .01 (.86) .13 (.09) —.14 (.07) — 
Macroidiff —.15 (.78) —1.04 (.13) .79 (.73) .40 (.83) .09 (.76) .24 (.37) —.33 (.27) — 
neut1 .53 (.48) —.26 (.81) —2.25 (.40) 1.97 (.44) —.43 (.51) .66 (.57) —.22 (.64) — 
neut2 .08 (.97) .07 (.98) 3.58 (.64) —3.73 (.62) .10 (.90) 1.78 (.01) —1.88 (.02) — 
neutidiff —.77 (.61) —.01 (.99) 6.65 (.24) —5.87 (.31) .53 (.55) 1.12 (.16) —1.65 (.07) — 
lymphl .73 (.36) —5.23 (.03) .26 (.92) 4.25 (.20) 2.09 (.03) —1.12 (.18) —.97 (.29) — 
lymph2 .89 (.50) —.77 (.55) —1.45 (.78) 1.33 (.77) —.32 (.69) —.93 (.20) 1.25 (.12) — 
lymphidiff 1.51 (.46) —.88 (.69) —3.87 (.60) 3.23 (.63) —2.20 (.02) .01 (.99) 2.19 (.02) — 
pneutl —3.37 (.06) 8.09 (.05) —4.49 (.36) —.22 (.97) —4.87 (.17) 4.11 (.20) .76 (.82) — 
pneut2 — — — — 1.56 (.69) 5.44 (.16) —7.00 (.07) — 
pneutidiff — — — — 8.57 (.10) —2.10 (.64) —6.47 (.20) — 
Plymphl 1.68 (.18) —14.4 (.005) 3.03 (.44) 9.65 (.08) 6.45 (.08) —4.69 (.14) —1.76 (.61) — 
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TABLE 2a-c0ntinued 
NRAMP1 Ava11 genotype association 
analysis in example 1. 
Allele substitution effects (p value) 
LineA Line B 
TRAITa 1-all 2-all 3-all 4-all 1-all 2-all 3-all 4-all 
Plymph2 — — — — —4.19 (.36) —5.17 (.23) 9.36 (.05) — 
Plymphid — — — — —11.0 (.03) 1.8 (.67) 9.19 (.07) — 
aTraits are: 
TEMPDO = temperature on day 0 of challenge, 
TEMPD1 — temperature on day 1 after challenge, etc.; 
FMPND6 = mean fecal Salmonella count on day 6 after challenge; 
Macro1 and 2 = macrophage numbers before (1) and after (2) challenge; 
Macroidiff = difference in macrophage numbers before and after challenge; 
lymph 1, 2, diff = lymphocyte numbers before (1) and after (2) challenge and the difference betWeen these values; 
pneut1, 2, diff = percentage of neutrophils before (1) and after (2) challenge and the difference betWeen these values; 
plymph 1, 2, diff = percentage of lymphocytes before (1) and after (2) challenge and the difference betWeen these values. 
TABLE 2b 
NRAMP1 Avall genotype association analysis 25 
(lines combined) in example 1. 
Allele substitution effects (p-value) 
Lines A and B combined 
TRAITa 1-all 2-all 3-all 4-all 3O 
FMPND6 —.56 (.06) -.51 (.19) .14 (.73) .92 (.28) 
aFMPND6 = mean fecal Salmonella count on day 6 after challenge 
TABLE 3 
NRAMP1 Smal genotype association 
analysis in example 1. 
Line A Line B 
LSmeans (s.e.) LSmeans (s.e.) 
TRAITa 66 67 77 P 66 67 77 p 
FMPND6 .70 (.91) 1.15 (1.0) .41 (2.1) 0.85 .14 (.25) -1.02 (.45) _ 0.04 
aFMPND6 = mean fecal Salmonella count on day 6 after challenge 
TABLE 4 5O 
NRAMP1 NIalll genotype association analysis 
(lines combined) in example 1. 
55 
Line A and B combined 
LSmeans (s.e.) 
6O 
TRAITa 88 89 99 p 
FMPND6 1.19 (0.15) 2.27 (0.45) _ .0006 
65 
aFMPND6 = mean fecal Salmonella count on day 6 after challenge 
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TABLE 5 
30 
NRAMP1 MspAl genotype association 
analysis in example 1. 
Line A Line B 
LSmeans (s.e.) LSmeans (s.e.) 
TRAIT“ 44 45 55 p 44 45 55 p 
FMPND6 -.11 (1.3) 1.3 (1.0) 1.2 (.90) 0.71 —.46 (.86) —.87 (.36) .24 (.23) 0.06 
aFMPND6 = mean fecal Salmonella count on day 6 after challenge 
15 Experiment Description 
TABLE 6 Challenged pigs Were offspring of a reference population 
that Was bred from sires Was that differed in susceptibility to 
Genotype frequencies Within challenge Population Salmonellosis. The founder sires (commercial line Y) Were 
11 12 13 22 23 33 selected based on the results of a preliminary study to 
20 identify individuals that differed in susceptibility to infection 
NRAMPl-Hin? Line — — — 9 5 1 With S. choleraesuis. Sires Were mated to 23 F1 gilts (crosses 
?ne _ 8 2 29 5 _ of commercial lines Y><Z and Z><Y) and produced one litter. 
B Three to nine piglets from each litter Were selected for oral 
challenge With 8x108 S. choleraesuis (n=216). Piglets Were 
11 12 13 14 22 23 24 33 34 44 25 challenged at 6 Weeks of age. Blood samples Were taken 
NR AMP1_ Avail Line 5 6 _ _ 2 _ 1 _ 1 _ from animals for innate immunity studies one Week before 
A challenge, on the day of challenge and at necropsy. Traits of 
Line 4 13 14 — 5 5 — 3 — — innate immunity included total leukocyte count and 
B differential, bacterial uptake, phagocytosis and killing by 
66 67 77 30 neutrophils, lymphocyte proliferation against several anti 
gens (Table Ex2—4). One Week after challenge, animals Were 
NRAMPl-Smal Line 9 4 2 necropsied and the amount of Salmonella in liver and spleen 
A_ Was determined by quantitative culture on one gram of 
Iéme 37 7 — tissue. 
35 DNA Was also isolated from blood for genetic analysis. Pigs 
88 89 99 Were genotyped by using several NRAMP1 marker systems 
_ described above; genotype frequencies are shoWn in Table 
NRAMPl'NIam line 10 5 — Ex2-1. Statistical associations between genotypes and mea 
Line 42 _ _ sured traits are shoWn in Table Ex2-2 and Ex2-3. 
B 40 Statistical Treatment of Data 
The associations between the sequence polymorphisms and 
44 45 55 phenotypes Were tested using mixed model procedures 
NRAMP1_MSPA1 Line 4 5 6 (SASTM procedure MIXED) With a model Which alWays 
A included dam as a random effect and Group and marker 
Line 2 1O 32 45 parameters as ?xed effects. Single point signi?cance values 
B are reported, Without making adjustments for multiple com 
parisons. 
Multiallelic Markers 
EXAMPLE 2 For our markers With more than 2 alleles (NrampAva-II in 
Bacterial Challenge and Association Testing 50 this population) the folloWing mixed model Was used to 
Summary estimate allele substitution effects, Where soWid Was random 
To further assess the utility of the marker tests to identify and the Other effects are ?Xed 
animals that differ in innate disease resistance, some of these 
markers Were tested on offspring of sires that Were suscep- Trait=sowid+group“H6161+ane1e2+anele3' 
tible or resistant to Salmonellosis. The offspring Were‘ chal- 55 Each allele Was put in the model as a ?xed effect With 3 
lenged ~orally With S. choleraesuzs and infection and innate levels (_1,0 and 1) For allele “1” these Values would be _1 
immunity related traits Were measured. Association analyses for a “not_l/not_l” genotype, 0 for a“1/nOt_1” genotype and 
revealed the‘? potentlal effects of NRAMPl genotype on 1 for a “1/ 1” genotype. Allele substitution effects Were 
fever’ bactenal load In hver and Spleen’ and lmfmfne Cell estimated and presented With allele 3 arbitrarily set to Zero. 
numbers and function. The presence of bacteria in internal 6O Bi_anelic Markers 
organs demonstrates that the animal’s immune system Was For our markers With 2 alleles (NrampHin? in this 
unable to control spread of the infection. Reduced bacterial population) the following mixed model Was used to estimate 
counts and loWer fever in one genotype class are indicative Least Square means (LS means) for the 3 genotype Classes, 
of the heightened ability of those animals to control infec- With SOWid as random effect and group and genotype as ?xed 
tion. These traits have economic value since fever and 65 
systemic infection decrease appetite and suppress groWth 
and perfomance in a measurable Way. 
effects. 
Trait=soWid+group+genotype 
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Results and Discussion 
Overall results are summarized in the following tables 
(Tables EX2-2 and EX2-3; trait descriptions are in Table 
EX2-4). The bacterial count data (SpleenC and LiverC) Was 
log transformed because of the non-normal distribution of 
32 
the marker. All comparisons are shoWn for trait and marker 
systems Where suf?ciently informative markers for statisti 
cal analysis Were available. 
TABLE EX2-1 
the data, a Widely accepted treatment for non-normally 
distributed data sets. _ _ _ _ 
AS can be Seen from the data in Example 2, NRAMPl Genotype frequencies Within example 2 population. 
AvaII and HinfI genotypes are associated With differences in 
the level of bacterial infection and clearance, as noted from 10 NRAMPl' genotype 11 12 13 22 23 33 total 
statistically signi?cant association With spleen and liver Avall number 17 45 63 15 21 17 178* 
counts; With several traits measuring phagocytic activity; percentage 10 25 35 8 12 10 100 
and With the level of fever associated With infection. In 
addition, vvhite blood cell count before or after infection NRAMP1_ genotype 11 12 22 total 
Were associated With NRAMP1 genotypes. These cells are 15 _ 
critical for controlling and recovering from infection. The Hm? number 15 66 95 176* 
number of White blood cells and their ability to respond to Percentage 9 37 54 100 
infection. 
Some alleles are found to be associated With traits in only *not all animals genotyped for Hinfl 
one of the analyses, often due to lack of informativeness of 
TABLE EX2-2 
Nramp1 Avall genotype association analysis in example 2 
Allele 
substitution effect" contrast p-values 
Trait mean (s.e) s.d. 1 2 3 1 vs 2 1 vs 3 2 vs 3 
SpleenC 1.16 (0.09) 1.25 0.59 0.09 0 0.007 0.0012 0.56 
liverC 2.16 (0.11) 1.45 0.65 -0.02 0 0.0006 0.0006 0.91 
Wbc1 6.63 (0.30) 3.91 -0.36 -0.23 0 0.75 0.39 0.45 
wbe2 7.23 (0.23) 3.01 -0.68 -0.94 0 0.49 0.08 0.009 
Wbc3 10.53 (0.34) 4.1 -0.54 0.87 0 0.04 0.45 0.17 
Wbcid12 0.57 (0.34) 4.46 -0.08 -0.84 0 0.19 0.90 0.07 
Wbcid23 3.14 (0.38) 4.58 0.02 1.67 0 0.03 0.98 0.02 
Wbcid13 3.56 (0.40) 4.79 -0.52 0.86 0 0.08 0.53 0.21 
l’l’lOl’ll 2.94 (0.19) 2.47 -0.26 -0.70 0 0.21 0.48 0.04 
inon2 2.40 (0.14) 1.88 0.23 -0.07 0 0.31 0.45 0.79 
inon3 3.54 (0.24) 2.83 -0.31 -0.24 0 0.88 0.53 0.58 
l’nOnfdlZ -0.54 (0.21) 2.81 0.55 0.68 0 0.77 0.22 0.10 
SICAipre 222.4 (19.2) 253 81.10 0.73 0 0.05 0.05 0.98 
SICAipos 68.01 (8.64) 103 13.09 -17.57 0 0.10 0.50 0.33 
CAiLPSpr 44.93 (3.91) 51.3 9.95 -6.05 0 0.06 0.25 0.40 
CAiLPSpo 16.99 (3.06) 36.6 0.70 -6.71 0 0.26 0.92 0.29 
uptake 0.54 (0.11) 1.41 -0.07 0.29 0 0.09 0.74 0.11 
killing 83.48 (1.57) 20.6 -6.54 1.63 0 0.01 0.05 0.59 
phagoc 3.38 (0.56) 7.3 -0.83 0.91 0 0.03 0.32 0.18 
percipmn 73.63 (1.19) 15.6 -1.99 -6.89 0 0.04 0.42 0.003 
t1 39.48 (0.04) 0.35 0.06 0.03 0 0.69 0.35 0.64 
t2 39.55 (0.04) 0.34 0.12 0.04 0 0.29 0.08 0.54 
t3 38.91 (0.03) 0.27 0.02 0.07 0 0.36 0.76 0.23 
t4 39.58 (0.04) 0.33 0.03 0.04 0 0.92 0.68 0.62 
t5 39.64 (0.05) 0.49 -0.02 -0.04 0 0.85 0.86 0.72 
t6 40.83 (0.09) 0.82 -0.31 -0.19 0 0.53 0.07 0.30 
t7 41.51 (0.04) 0.38 -0.06 -0.10 0 0.71 0.46 0.27 
t8 41.37 (0.04) 0.35 0.24 0.06 0 0.02 0.0007 0.42 
t9 40.90 (0.06) 0.52 0.07 -0.09 0 0.21 0.56 0.39 
r10 40.80 (0.06) 0.57 0.08 -0.26 0 0.01 0.49 0.03 
r11 40.30 (0.08) 0.68 0.16 -0.14 0 0.07 0.28 0.36 
r12 40.40 (0.06) 0.57 -0.03 -0.02 0 0.97 0.82 0.84 
*Allele 3 set to Zero for these comparisons 
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TABLE EX2-3 
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Nramp1 Hinfl genotype association analysis in example 2 
l Smean (s.e.) 
Trait 11 12 22 
SpleenC 0.77 (0.32) a 1.29 (0.16) b 1.20 (0.14) b 
liverC 1.64 (0.33) e c 2.33 (0.17) f 2.29 (0.15) d 
Wbc1 6.80 (0.63) a 6.11 (0.36) b 6.59 (0.34) a 
Wbc2 6.51 (0.67) a 6.67 (0.32) e 7.53 (0.27) b f 
Wbc3 12.18 (1.11) a c 10.74 (0.61) b 9.81 (0.48) a d 
WlIJCfdlZ —0.73 (0.90) a c 0.49 (0.49) b 1.12 (0.45) a d 
WbCfdZf? 5.91 (1.24) a e 3.89 (0.69) b c 2.40 (0.52) f d 
WbCid13 4.99 (1.22) a 4.36 (0.69) a 3.10 (0.56) b 
mon1 2.16 (0.62) a 2.43 (0.29) c 3.14 (0.25) b d 
mon2 2.23 (0.50) 2.17 (0.25) 2.43 (0.22) 
mon3 3.77 (0.78) 3.19 (0.42) 3.59 (0.34) 
monid12 0.10 (0.77) —0.30 (0.36) —0.75 (0.31) 
SICAipre 178.3 (69.1) 212.6 (33.0) 244.2 (28.7) 
SICAipos 17.57 (31.9) a c 67.43 (16.5) b 79.67 (13.4) d 
CAiLPSpr 39.69 (13.8) 37.82 (6.95) c 52.59 (6.08) d 
CAiLPSpo 3.57 (11.3) a 16.26 (5.81) 20.86 (4.69) b 
uptake 0.88 (0.35) a 0.66 (0.17) c 0.30 (0.15) b d 
killing 84.37 (5.83) 86.78 (2.84) c 79.74 (2.48) d 
phagoc 5.67 (1.31) c e 3.19 (0.68) d 2.53 (0.61) f 
percipmn 67.31 (4.21) e 70.87 (1.96) g 77.92 (1.68) f h 
t1 39.28 (0.18) a 39.57 (0.07) a,b 39.48 (0.04) b 
t2 39.46 (0.18) 39.62 (0.08) 39.56 (0.05) 
t3 39.01 (0.15) 38.97 (0.06) a 38.90 (0.03) b 
t4 39.54 (0.19) 39.62 (0.08) 39.57 (0.04) 
t5 39.49 (0.28) 39.65 (0.11) 39.65 (0.06) 
t6 40.40 (0.48) 40.90 (0.19) 40.82 (0.11) 
t7 41.64 (0.22) a 41.36 (0.09) b c 41.54 (0.05) d 
t8 41.50 (0.21) 41.40 (0.09) 41.37 (0.06) 
t9 40.78 (0.27) 40.84 (0.13) 40.96 (0.10) 
t10 40.53 (0.35) a 40.58 (0.13) e 40.90 (0.09) b f 
t11 39.91 (0.39) a 40.18 (0.17) 40.34 (0.11) b 
t12 40.35 (0.31) 40.44 (0.14) 40.44 (0.09) 
LSmeans signi?cance levels betWeen genotypes With different subscripts: 
g—h p < .01 o—p p < .0001 
TABLE EX2-4 
Trait Code Trait description 
CA/LPS1 Stimulation indeX in presence of Concavalin A + SCS A50 
LPS on day 29 
CA/LPS2 Stimulation indeX in presence of Concavalin A + SCS A50 
LPS on day 38 
killing Salmonella killing e?iciency of PMNs 
LiverC Bacterial counts in liver at one Week 
Lymfo1 percentage lymphocytes on day 15 
Lymfo2 percentage lymphocytes on day 29 
Lymfo3 percentage lymphocytes on day 38 or post mortem 
Mono1 percentage monocytes on day 15 
Mono2 percentage monocytes on day 29 
Mono3 percentage monocytes on day 38 or post mortem 
monoid12 absolute value of mono1-mono2 
monoid23 absolute value of mono2-mono3 
monoid13 absolute value of mono1-mono1 
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TABLE EX2-4-continued 
Trait Code Trait description 
Neutro1 percentage neutrophils on day 15 
Neutro2 percentage neutrophils on day 29 
Neutro3 percentage neutrophils on day 38 or post mortem 
Pcv1 packed cell volume on day 15 
Pcv2 packed cell volume on day 29 
Pcv3 packed cell volume on day 38 or post mortem date 
percipmn percentage PMN’s 
phag phagocytosis e?iciency of PMN’s 
SICAipos Stimulation indeX in presence of Concavalin A on day 38 
SICAipre Stimulation indeX in presence of Concavalin A on day 29 
SpleenC Bacterial counts in spleen at one Week 
uptake Salmonella uptake e?iciency of PMN’s 
Wbc1 White blood cell count on day 15 
Wbc2 White blood cell count on day 29 
Wbc3 White blood cell count on day 38 or post mortem. 
Wbcid12 absolute value of Wbc1-Wbc2 
WlIJCid23 absolute value of Wbc2-Wbc3 
WlIJCid13 absolute value of Wbc1-Wbc3 
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Overall Summary 
In both Examples, NRAMP1 genotypes are associated 
With speci?c measures of innate disease resistance and 
disease susceptibility such as fever, systemic infection and 
immune function. Thus this information and marker systems 
to determine NRAMP1 genotypes can be used to improve 
animal health and performance due to the ability to decrease 
incidence of disease through identifying susceptible animals 
before they can become sick. Alternatively, the same tech 
nologies described above can be used to identify those 
animals most likely to be the healthiest Within a group. 
Improving these traits have economic value since fever and 
systemic infection decrease appetite and suppress groWth 
and perfomance. 
SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 9 
<2 10> SEQ ID NO 1 
<2ll> LENGTH: 21 




